aspirin and Vascular Diseases studies

Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.

Vascular Diseases: Pathological processes involving any of the BLOOD VESSELS in the cardiac or peripheral circulation. They include diseases of ARTERIES; VEINS; and rest of the vasculature system in the body.

Research Excerpts

Excerpt	Relevance	Reference
"A total of 7554 patients with atrial fibrillation who had an increased risk of stroke and for whom vitamin K-antagonist therapy was unsuitable were randomly assigned to receive clopidogrel (75 mg) or placebo, once daily, in addition to aspirin."	9.14	Effect of clopidogrel added to aspirin in patients with atrial fibrillation. ( Chrolavicius, S; Connolly, SJ; Hart, RG; Hohnloser, SH; Pfeffer, M; Pogue, J; Yusuf, S, 2009)
"In CHARISMA, there was an increased risk of bleeding with long-term clopidogrel."	9.14	Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHAR ( Berger, PB; Bhatt, DL; Brennan, DM; Fox, KA; Fuster, V; Hacke, W; Montalescot, G; Shao, M; Steg, PG; Steinhubl, SR; Topol, EJ, 2010)
"The trial did not meet the predefined criteria for noninferiority but showed similar rates of recurrent stroke with ASA-ERDP and with clopidogrel."	9.13	Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. ( Albers, GW; Bath, P; Bornstein, N; Chan, BP; Chen, ST; Cotton, D; Cunha, L; Dahlöf, B; De Keyser, J; Diener, HC; Donnan, GA; Estol, C; Gorelick, P; Gu, V; Hermansson, K; Hilbrich, L; Kaste, M; Lawton, WA; Lu, C; Machnig, T; Martin, RH; Ounpuu, S; Pais, P; Palesch, Y; Roberts, R; Sacco, RL; Skvortsova, V; Teal, P; Toni, D; Vandermaelen, C; Voigt, T; Weber, M; Yoon, BW; Yusuf, S, 2008)
"The combination of aspirin with anticoagulant is associated with increased bleeding in elderly atrial fibrillation patients."	9.09	Anticoagulant (fluindione)-aspirin combination in patients with high-risk atrial fibrillation. A randomized trial (Fluindione, Fibrillation Auriculaire, Aspirin et Contraste Spontané; FFAACS). ( Chaumet-Riffaud, P; Derumeaux, G; Lacomblez, L; Lardoux, H; Lechat, P; Lecompte, T; Maillard, L; Mallet, A; Mas, JL; Mentre, F; Pisica, G; Pousset, F; Raynaud, P; Sanchez, P; Solbes-Latourette, S, 2001)
"Long-term aspirin therapy is crucial for patients with increased risk of occlusive vascular diseases."	7.78	Knowledge, attitudes and current practice of Jordanian family physicians about prescribing aspirin in primary and secondary prevention of vascular diseases: a self-reported survey. ( Al Omari, M; Al-azzam, SI; Alomari, N; Alzoubi, KH; Dauod, AS; Khader, Y; Khassawneh, AH, 2012)
"Low-risk essential thrombocythemia patients include patients aged 18 to < 80 years with no vascular risk factor or previous thrombosis, no associated disease, a normal life expectancy, and a platelet count between 400 and 1,000 x 10(9)/L up to 1,500 x 10(9)/L."	6.40	Aspirin and platelet-lowering agents for the prevention of vascular complications in essential thrombocythemia. ( Michiels, JJ, 1999)
"Thirty-six randomized control trials of aspirin compared with another dosage of aspirin or with placebo."	6.39	Efficacy and safety of different aspirin dosages on vascular diseases in high-risk patients. A metaregression analysis. ( Cappelleri, JC; Chalmers, TC; Kupelnick, B; Lau, J, 1995)
" Conditions characterized by a reduction in platelet survival and where dipyridamole has been used include heart valve replacement, arterial grafting, cerebrovascular disorders, and disorders of peripheral circulation."	6.15	Dipyridamole: a critical evaluation. ( Alexander, MR; Rivey, MP; Taylor, JW, 1984)
"A total of 7554 patients with atrial fibrillation who had an increased risk of stroke and for whom vitamin K-antagonist therapy was unsuitable were randomly assigned to receive clopidogrel (75 mg) or placebo, once daily, in addition to aspirin."	5.14	Effect of clopidogrel added to aspirin in patients with atrial fibrillation. ( Chrolavicius, S; Connolly, SJ; Hart, RG; Hohnloser, SH; Pfeffer, M; Pogue, J; Yusuf, S, 2009)
"The Japanese Primary Prevention Project (JPPP) is a multicenter, open-label, randomized, parallel-group trial that is evaluating primary prevention with low-dose aspirin in Japanese patients aged 60 to 85 years with hypertension, dyslipidemia, or diabetes mellitus."	5.14	Rationale, design, and baseline data of the Japanese Primary Prevention Project (JPPP)-a randomized, open-label, controlled trial of aspirin versus no aspirin in patients with multiple risk factors for vascular events. ( Ando, K; Goto, Y; Ikeda, Y; Ishizuka, N; Murata, M; Oikawa, S; Shimada, K; Sugawara, M; Teramoto, T; Uchiyama, S; Yamada, N; Yamazaki, T; Yokoyama, K, 2010)
"In CHARISMA, there was an increased risk of bleeding with long-term clopidogrel."	5.14	Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHAR ( Berger, PB; Bhatt, DL; Brennan, DM; Fox, KA; Fuster, V; Hacke, W; Montalescot, G; Shao, M; Steg, PG; Steinhubl, SR; Topol, EJ, 2010)
"The trial did not meet the predefined criteria for noninferiority but showed similar rates of recurrent stroke with ASA-ERDP and with clopidogrel."	5.13	Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. ( Albers, GW; Bath, P; Bornstein, N; Chan, BP; Chen, ST; Cotton, D; Cunha, L; Dahlöf, B; De Keyser, J; Diener, HC; Donnan, GA; Estol, C; Gorelick, P; Gu, V; Hermansson, K; Hilbrich, L; Kaste, M; Lawton, WA; Lu, C; Machnig, T; Martin, RH; Ounpuu, S; Pais, P; Palesch, Y; Roberts, R; Sacco, RL; Skvortsova, V; Teal, P; Toni, D; Vandermaelen, C; Voigt, T; Weber, M; Yoon, BW; Yusuf, S, 2008)
" The recently published European/Australasian Stroke Prevention in Reversible Ischaemia Trial (ESPRIT), an open-label randomised controlled study, compared long-term treatment of patients randomised to aspirin 30-325 mg daily with (n = 1363) or without (n = 1376) dipyridamole 200 mg twice daily."	5.12	ESPRIT study design and outcomes--a critical appraisal. ( Einhäupl, K, 2007)
"The combination of aspirin with anticoagulant is associated with increased bleeding in elderly atrial fibrillation patients."	5.09	Anticoagulant (fluindione)-aspirin combination in patients with high-risk atrial fibrillation. A randomized trial (Fluindione, Fibrillation Auriculaire, Aspirin et Contraste Spontané; FFAACS). ( Chaumet-Riffaud, P; Derumeaux, G; Lacomblez, L; Lardoux, H; Lechat, P; Lecompte, T; Maillard, L; Mallet, A; Mas, JL; Mentre, F; Pisica, G; Pousset, F; Raynaud, P; Sanchez, P; Solbes-Latourette, S, 2001)
"In the overall population, dual antiplatelet therapy (DAPT) with aspirin and clopidogrel in comparison to aspirin monotherapy reduced the relative risk of total stroke by 20% (risk ratio [RR], 0."	4.90	Antiplatelet treatment for prevention of cerebrovascular events in patients with vascular diseases: a systematic review and meta-analysis. ( Arrich, J; Gouya, G; Gurbel, PA; Huber, K; Pirker-Kees, A; Siller-Matula, JM; Verheugt, FW; Wolzt, M, 2014)
"To review the rationale, clinical practice guideline recommendations, and clinical trial data describing bleeding and clinical outcomes associated with the use of the combination of aspirin, a thienopyridine, and warfarin."	4.84	Aspirin, clopidogrel, and warfarin: is the combination appropriate and effective or inappropriate and too dangerous? ( Hermosillo, AJ; Spinler, SA, 2008)
"Meta-analyses of randomised clinical trials in patients with TIA and ischaemic stroke of arterial origin indicate that, compared with control, the relative risk reduction (RRR) for recurrent stroke and other serious vascular events is 13% (95% confidence interval [CI] 6% to 19%) with aspirin, 13% (4% to 21%; p = 0."	4.84	Antiplatelet therapy for the prevention of recurrent stroke and other serious vascular events: a review of the clinical trial data and guidelines. ( Hankey, GJ, 2007)
" Outcomes included 6 clinical quality measures of being up to date for colorectal cancer screening, cervical cancer screening, tobacco screening and cessation counseling, BMI screening and follow-up, depression screening and follow-up, and aspirin use for ischemic vascular disease."	4.31	The First Year of the COVID-19 Pandemic: Changes in Preventive Services in Community Health Centers. ( Bandi, P; Han, X; Jemal, A; Makaroff, LA; Minihan, AK; Star, J, 2023)
" Upper gastrointestinal bleeding is a serious complication, but had low case fatality in trials of aspirin and is not generally thought to cause long-term disability."	3.85	Age-specific risks, severity, time course, and outcome of bleeding on long-term antiplatelet treatment after vascular events: a population-based cohort study. ( Geraghty, OC; Li, L; Mehta, Z; Rothwell, PM, 2017)
"Previous DAPT studies consistently demonstrated greater efficacy but an increased risk of bleeding compared with aspirin alone in patients with acute coronary syndromes or undergoing percutaneous coronary intervention."	3.76	Role of dual antiplatelet therapy in symptomatic patients with established vascular disease: putting the CHARISMA trial into therapeutic perspective. ( Bhatt, DL; Boden, WE; Flather, MD, 2010)
"60."	2.79	Triflusal and aspirin in the secondary prevention of atherothrombotic ischemic stroke: a very long-term follow-up. ( Alvarez-Sabín, J; Maisterra, O; Quintana, M; Santamarina, E, 2014)
"To determine whether urinary 11-dehydrothromboxane B2 (d-TXB2) is a marker of aspirin resistance and define the relationship between aspirin dosage and concentrations of this thromboxane metabolite."	2.71	Aspirin dosage and thromboxane synthesis in patients with vascular disease. ( Bovill, E; Cornell, E; Feinberg, WM; Hart, RG; Leonard, AD; Pearce, LA; Talbert, RL, 2003)
"Patients with 50 to 99% stenosis of an intracranial artery (carotid; anterior, middle, or posterior cerebral; vertebral; or basilar) were identified by reviewing the results of consecutive angiograms performed at participating centers between 1985 and 1991."	2.68	The Warfarin-Aspirin Symptomatic Intracranial Disease Study. ( Brown, MB; Chimowitz, MI; Furlan, AJ; Kokkinos, J; Levine, SR; Pessin, MS; Sila, CA; Silliman, S; Strong, J; Weichel, E, 1995)
"Aspirin is a safe, though less effective, alternative when anticoagulation is contraindicated; it prevents 40 vascular events each year for every 1000 treated patients."	2.67	Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group. ( , 1993)
" Currently available antiplatelet drugs have some limitations which might be overcomed by improved dosing regimens, use of combination of agents affecting different platelet functions and, in particular, by the new antiplatelet drugs (new arterial antithrombotics) with distinct pharmacodynamic properties offering new advantages, including faster onset of action, greater potency, and reversibility of effects."	2.49	[Present and future of pharmaco-arteriothromboprophylaxis in clinical practice. Guidelines of Angiology Section of Slovak Medical Chamber]. ( Dukát, A; Gašpar, L; Gavornik, P, 2013)
"Patients with Type 2 diabetes carry an equivalent cardiovascular risk to that of a non-diabetic individual who has already experienced a coronary event."	2.47	Management of type-2 diabetes with anti-platelet therapies: special reference to aspirin. ( Rao, GH, 2011)
"Aspirin non-response was more frequently associated with the use of "home-established" cut-offs or when closure time was only assessed after aspirin (rather than both before and after)."	2.44	Response variability to aspirin as assessed by the platelet function analyzer (PFA)-100. A systematic review. ( Cerletti, C; Crescente, M; de Gaetano, G; Di Castelnuovo, A; Iacoviello, L; Vermylen, J, 2008)
"Chuvash polycythemia is characterized by a homozygous 598C> T germline mutation in the von Hippel-Lindau gene ( VHL), upregulation of hypoxia-inducible factor-1alpha during normoxia, and resulting augmentation of erythropoietin and several other hypoxia-controlled genes."	2.43	Vascular complications in Chuvash polycythemia. ( Gordeuk, VR; Prchal, JT, 2006)
"Aspirin is an effective antithrombotic agent for many patients."	2.42	[Aspirin resistance]. ( Balbay, Y; Korkmaz, S; Yilmaz, MB, 2004)
"Aspirin also has been studied and is effective, but with a more modest benefit (relative risk reduction of 22%)."	2.42	Prevention of vascular events in patients with atrial fibrillation: evidence, guidelines, and practice. ( Connolly, SJ, 2003)
"Aspirin resistance has been reported in patients with cardiovascular, cerebrovascular, and peripheral vascular disease."	2.41	Aspirin resistance. ( Howard, PA, 2002)
"Low-risk essential thrombocythemia patients include patients aged 18 to < 80 years with no vascular risk factor or previous thrombosis, no associated disease, a normal life expectancy, and a platelet count between 400 and 1,000 x 10(9)/L up to 1,500 x 10(9)/L."	2.40	Aspirin and platelet-lowering agents for the prevention of vascular complications in essential thrombocythemia. ( Michiels, JJ, 1999)
"Thirty-six randomized control trials of aspirin compared with another dosage of aspirin or with placebo."	2.39	Efficacy and safety of different aspirin dosages on vascular diseases in high-risk patients. A metaregression analysis. ( Cappelleri, JC; Chalmers, TC; Kupelnick, B; Lau, J, 1995)
"Vascular images revealed stenosis from the distal internal carotid artery (ICA) to the middle cerebral artery (MCA)."	1.91	Progressive arteriopathy with vasospasm in focal cerebral arteriopathy in childhood: a case report. ( Fujii, N; Hasegawa, S; Inoue, H; Ishihara, H; Nishimoto, T; Nomura, S; Oka, F; Yamane, M, 2023)
"Evidence for cancer prophylaxis is based on ASA doses of at least 75mg/day."	1.43	Aspirin for cancer is no mere antiplatelet prototype. There is potential in its ancient roots. ( Baxter, GJ; Lawrence, JR; Paterson, JR, 2016)
"The primary outcome was first recurrence of stroke of any type and the secondary outcome was a composite of stroke, myocardial infarction, or death from vascular causes."	1.37	Level of systolic blood pressure within the normal range and risk of recurrent stroke. ( Bath, PM; Cotton, D; Diener, HC; Donnan, GA; Martin, RH; Ovbiagele, B; Vinisko, R; Yusuf, S, 2011)
"The metabolic syndrome is present in about half of individuals with symptomatic intracranial atherosclerotic disease and is associated with a substantially higher risk of major vascular events."	1.33	Impact of metabolic syndrome on prognosis of symptomatic intracranial atherostenosis. ( Chimowitz, M; Lynn, MJ; Ovbiagele, B; Saver, JL, 2006)
"Aspirin was both less expensive and more effective than clopidogrel in post-myocardial infarction patients."	1.32	Clopidogrel versus aspirin for secondary prophylaxis of vascular events: a cost-effectiveness analysis. ( Owens, DK; Schleinitz, MD; Weiss, JP, 2004)
"Aspirin was administered during the entire course, low molecular weight heparin (LMWH) preoperatively and as of the fourth postoperative (pOP) day and unfractionated heparin (UH) upon surgery and three days thereafter."	1.29	Platelet response to vascular surgery--a preliminary study on the effect of aspirin and heparin. ( Greinacher, A; Lasser, R; Reininger, AJ; Reininger, CB; Schweiberer, L; Steckmeier, B, 1994)
"Chronic urticaria is a relatively common disease with no known etiology."	1.27	Chronic urticaria. Possible causes, suggested treatment alternatives. ( Kaplan, AP, 1983)

Research

Studies (208)

Authors

Clinical Trials (14)

Trial Overview

Trial Outcomes

All-cause Mortality

Timeframe	Studies, this research(%)	All Research%
pre-1990	62 (29.81)	18.7374
1990's	30 (14.42)	18.2507
2000's	54 (25.96)	29.6817
2010's	52 (25.00)	24.3611
2020's	10 (4.81)	2.80

Authors	Studies
Xiang, F	1
Lin, Y	1
Chen, B	1
Khan, H	1
Kanny, O	1
Syed, MH	1
Qadura, M	1
Star, J	1
Han, X	1
Makaroff, LA	1
Minihan, AK	1
Jemal, A	1
Bandi, P	1
Nishimoto, T	1
Oka, F	1
Fujii, N	1
Inoue, H	1
Hasegawa, S	1
Yamane, M	1
Nomura, S	1
Ishihara, H	1
Gallagher, H	1
Lown, M	1
Fuat, A	1
Roderick, P	1
Oluwole, AS	1
Virk, HUH	1
Witzke, C	1
Patti, G	1
Sticchi, A	1
Renda, G	1
Regragui, H	1
Boussaadani, BE	1
Sasbou, L	1
Bouhdadi, H	1
Wazaren, H	1
Cherti, M	1
McCaw, ZR	1
Fitzmaurice, G	1
Wei, LJ	1
Fox, KAA	2
Tefferi, A	1
Szuber, N	1
Pardanani, A	1
Hanson, CA	1
Vannucchi, AM	1
Barbui, T	1
Gangat, N	1
Li, L	1
Geraghty, OC	1
Mehta, Z	1
Rothwell, PM	2
Shiran, A	1
Adawi, S	1
Rubinshtein, R	1
Bardicef, M	1
Gutterman, E	1
Blackwood, B	1
Lee, S	1
Liebmann, O	1
Binder, W	1
Kötter, I	1
Stübiger, N	1
Deuter, C	1
Peled, Y	1
Lavee, J	1
Raichlin, E	1
Katz, M	1
Arad, M	1
Kassif, Y	1
Peled, A	1
Asher, E	1
Elian, D	1
Har-Zahav, Y	1
Shlomo, N	1
Freimark, D	1
Goldenberg, I	1
Klempfner, R	1
Florczak, AS	1
Henni, S	1
Signolet, I	1
Hamel, JF	1
Humeau-Heurtier, A	1
Rousseau, P	1
Abraham, P	1
Calabrò, P	1
Gragnano, F	1
Visconti, LO	1
Tang, QJ	1
Lei, HP	1
Wu, H	1
Chen, JY	1
Deng, CY	1
Sheng, WS	1
Fu, YH	1
Li, XH	1
Lin, YB	1
Han, YL	1
Zhong, SL	1
Eikelboom, JW	2
Anand, SS	1
Bhatt, DL	3
Bosch, J	1
Connolly, SJ	3
Harrington, RA	1
Steg, PG	2
Yusuf, S	5
Biccard, BM	1
Sigamani, A	1
Chan, MTV	1
Sessler, DI	1
Kurz, A	1
Tittley, JG	1
Rapanos, T	1
Harlock, J	1
Szalay, D	1
Tiboni, ME	1
Popova, E	1
Vásquez, SM	1
Kabon, B	1
Amir, M	1
Mrkobrada, M	1
Mehra, BR	1
El Beheiry, H	1
Mata, E	1
Tena, B	1
Sabaté, S	1
Zainal Abidin, MK	1
Shah, VR	1
Balasubramanian, K	1
Devereaux, PJ	1
Bendinelli, V	1
Lefebvre, P	1
Daper, A	1
Patel, MR	1
Gaba, P	1
Parikh, SA	1
Collins, MB	1
Lau, WC	1
Froehlich, JB	1
Jewell, ES	1
Montgomery, DG	1
Eng, KM	1
Shields, TA	1
Henke, PK	1
Eagle, KA	1
McGuire, LK	1
Hale, EK	1
Godwin, LS	1
Gavornik, P	1
Dukát, A	1
Gašpar, L	1
Gouya, G	1
Arrich, J	1
Wolzt, M	1
Huber, K	1
Verheugt, FW	1
Gurbel, PA	1
Pirker-Kees, A	1
Siller-Matula, JM	1
Alvarez-Sabín, J	1
Quintana, M	1
Santamarina, E	1
Maisterra, O	1
Smith, L	1
Cruickshank, R	1
Beattie, D	1
Burkes, M	1
Abdullah, AS	1
Ibrahim, H	1
Kiernan, TJ	1
Nizamuddin, SL	1
Broderick, DK	1
Minehart, RD	1
Kamdar, BB	1
Wang, LP	1
Zhang, XY	1
Liu, N	1
Ma, ZZ	1
Fang, DS	1
Patrono, C	2
Grandone, E	1
Villani, M	1
Tiscia, GL	1
Ahmed, Z	1
Bajwa, A	1
Bhardwaj, B	1
Laster, SB	1
Magalski, A	1
Wu, S	1
Liu, W	1
Zhou, Y	1
Chasseriaud, W	1
Tearney, GJ	1
Montaudon, M	1
Fialon, B	1
Coste, P	1
Gerbaud, E	1
Chaturvedi, S	1
Pieper, D	1
Levine, DL	1
Thati, N	1
Madhavan, R	1
Mateo, M	1
Cardozo, L	1
Lepczyk, MB	1
Lawrence, JR	1
Baxter, GJ	1
Paterson, JR	1
Wonnacott, D	1
Berringer, R	1
Mirra, M	1
Kola, N	1
Mattiello, G	1
Morisco, C	1
Spinelli, L	1
Sacco, RL	1
Diener, HC	2
Cotton, D	2
Ounpuu, S	1
Lawton, WA	1
Palesch, Y	1
Martin, RH	2
Albers, GW	1
Bath, P	1
Bornstein, N	1
Chan, BP	1
Chen, ST	1
Cunha, L	1
Dahlöf, B	1
De Keyser, J	1
Donnan, GA	2
Estol, C	1
Gorelick, P	1
Gu, V	1
Hermansson, K	1
Hilbrich, L	1
Kaste, M	1
Lu, C	1
Machnig, T	1
Pais, P	1
Roberts, R	1
Skvortsova, V	1
Teal, P	1
Toni, D	1
Vandermaelen, C	1
Voigt, T	1
Weber, M	1
Yoon, BW	1
Kunicki, TJ	1
Williams, SA	1
Nugent, DJ	1
Harrison, P	1
Segal, HC	1
Syed, A	1
Pogue, J	1
Hart, RG	2
Hohnloser, SH	1
Pfeffer, M	1
Chrolavicius, S	1
Thalhammer, C	1
Jankowski, J	1
Attwood, S	1
deCaestecker, J	1
Barr, H	1
Cleland, JG	1
Cornell, J	1
Chua, D	1
Legal, M	1
Shalansky, SJ	1
Sanada, Y	1
Kawano, Y	1
Mizuta, K	1
Egami, S	1
Hayashida, M	1
Wakiya, T	1
Fujiwara, T	1
Sakuma, Y	1
Hydo, M	1
Nakata, M	1
Yasuda, Y	1
Kawarasaki, H	1
Teramoto, T	1
Shimada, K	2
Uchiyama, S	2
Sugawara, M	1
Goto, Y	1
Yamada, N	1
Oikawa, S	1
Ando, K	1
Ishizuka, N	1
Yamazaki, T	1
Yokoyama, K	1
Murata, M	1
Ikeda, Y	2
Berger, PB	1
Fuster, V	1
Fox, KA	1
Shao, M	1
Brennan, DM	1
Hacke, W	1
Montalescot, G	1
Steinhubl, SR	2
Topol, EJ	1
Boden, WE	1
Flather, MD	1
Al Omari, M	1
Khader, Y	1
Al-azzam, SI	1
Dauod, AS	1
Khassawneh, AH	1
Alomari, N	1
Alzoubi, KH	1
Hennekens, CH	2
Schneider, WR	1
Pokov, A	1
Hetzel, S	1
Demets, D	1
Serebruany, V	2
Schröder, H	1
Rao, GH	1
Agirbasli, M	1
Eren, M	1
Eren, F	1
Murphy, SB	1
Serdar, ZA	1
Seckin, D	1
Zara, T	1
Cem Mat, M	1
Demirkesen, C	1
Vaughan, DE	1
Stewart, K	1
Walters, M	1
Dawson, J	1
Morgan, GP	1
Origasa, H	1
Goto, S	1
Okada, Y	1
Sugano, K	1
Hiraishi, H	1
Uemura, N	1
McNeil, J	1
Tonkin, A	1
Ovbiagele, B	2
Vinisko, R	1
Bath, PM	1
Turagam, MK	1
Velagapudi, P	1
Leal, MA	1
Kocheril, AG	1
Lafeber, M	1
Grobbee, DE	1
Spiering, W	1
van der Graaf, Y	1
Bots, ML	1
Visseren, FL	1
Douglas, IJ	1
Evans, SJ	1
Hingorani, AD	1
Grosso, AM	1
Timmis, A	1
Hemingway, H	1
Smeeth, L	1
Van Hattum, ES	1
Tangelder, MJ	1
Lawson, JA	2
Moll, FL	1
Algra, A	5
Reinhart, WH	1
Cuckle, H	1
von Dadelszen, P	1
Ghidini, A	1
Howard, PA	1
De Schryver, EL	3
van Gijn, J	4
Kovich, O	1
Otley, CC	1
Hankey, GJ	2
Leonard, AD	1
Talbert, RL	1
Pearce, LA	1
Cornell, E	1
Bovill, E	1
Feinberg, WM	1
FRICK, PG	1
PLAUCHU, M	2
DELAYE, J	1
GIRARD, R	1
TUFFANELLI, DL	1
DUBOIS, EL	1
Trinder, P	1
Rajaratnam, G	1
Lewis, M	1
Croft, P	1
Rodgers, JE	1
Yilmaz, MB	1
Balbay, Y	1
Korkmaz, S	1
Malinin, A	1
Spergling, M	1
Muhlestein, B	1
Steinhubl, S	1
Schleinitz, MD	1
Weiss, JP	1
Owens, DK	1
GIBSON, PC	1
Jones, L	1
Griffin, S	1
Palmer, S	1
Main, C	1
Orton, V	1
Sculpher, M	1
Sudlow, C	1
Henderson, R	1
Hawkins, N	1
Riemsma, R	1
Morgan, G	2
Niv, Y	1
Battler, A	1
Abuksis, G	1
Gal, E	1
Sapoznikov, B	1
Vilkin, A	1
Karnon, J	1
Brennan, A	1
Pandor, A	1
Fowkes, G	1
Lee, A	1
Gray, D	1
Coshall, C	1
Nicholls, C	1
Akehurst, R	1
Hughes, DA	1
Mehta, AB	1
Hansen, DB	1
Ambrosini, MV	1
Mariucci, G	1
Rambotti, MG	1
Tantucci, M	1
Covarelli, C	1
De Angelis, L	1
Del Soldato, P	1
Laguta, PS	1
Bavry, AA	1
Lincoff, AM	1
Gordeuk, VR	1
Prchal, JT	1
Saver, JL	1
Lynn, MJ	1
Chimowitz, M	1
Mani, H	1
Lindhoff-Last, E	1
Elwood, P	1
Longley, M	1
Einhäupl, K	1
Mattle, H	1
Niederkorn, K	1
Serebruany, VL	1
Malinin, AI	1
Atar, D	1
Hanley, DF	1
Shin, JI	1
Lee, JS	1
Ajjan, R	1
Storey, RF	1
Grant, PJ	1
Crescente, M	1
Di Castelnuovo, A	1
Iacoviello, L	1
Vermylen, J	2
Cerletti, C	1
de Gaetano, G	2
Santos, MT	2
Valles, J	2
Lago, A	2
Tembl, J	1
Sánchez, E	2
Moscardo, A	1
Cosin, J	2
Leung, FW	1
Lip, GY	1
Bowry, AD	1
Brookhart, MA	1
Choudhry, NK	1
Kapoor, JR	1
Hermosillo, AJ	1
Spinler, SA	1
Kaplan, AP	1
de Boer, AC	1
Genton, E	2
Turpie, AG	1
Webster, J	1
Majerus, PW	1
Weksler, BB	2
Rivey, MP	1
Alexander, MR	1
Taylor, JW	1
Strobl-Jäger, E	1
Kaliman, J	1
Sinzinger, H	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Randomized Controlled Trial of Rivaroxaban for the Prevention of Major Cardiovascular Events in Patients With Coronary or Peripheral Artery Disease (COMPASS - Cardiovascular OutcoMes for People Using Anticoagulation StrategieS).[NCT01776424]	Phase 3	27,395 participants (Actual)	Interventional	2013-02-28	Completed
A Large, International, Placebo-controlled, Factorial Trial to Assess the Impact of Clonidine and Acetyl-salicylic Acid (ASA) in Patients Undergoing Noncardiac Surgery Who Are at Risk of a Perioperative Cardiovascular Event[NCT01082874]	Phase 3	10,010 participants (Actual)	Interventional	2010-07-31	Completed
Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial[NCT00991029]	Phase 3	4,881 participants (Actual)	Interventional	2010-05-28	Terminated (stopped due to The trial was halted by the DSMB.)
PRoFESS - Prevention Regimen For Effectively Avoiding Second Strokes: A Double-blind, Active and Placebo Controlled Study of Aggrenox vs. Clopidogrel, With and Without Micardis[NCT00153062]	Phase 4	20,332 participants (Actual)	Interventional	2003-08-31	Completed
Aspirin Versus Aspirin + ClopidogRel as Antithrombotic Treatment Following Transcatheter Aortic Valve Implantation With the Edwards Valve. A Randomized Study (the ARTE Trial)[NCT02640794]	Phase 4	222 participants (Actual)	Interventional	2015-01-31	Completed
A Parallel Randomized Controlled Evaluation of Clopidogrel Plus Aspirin, With Factorial Evaluation of Irbesartan, for the Prevention of Vascular Events, in Patients With Atrial Fibrillation[NCT00249873]	Phase 3	7,554 participants (Actual)	Interventional	2003-06-30	Completed
Aspirin Versus Aspirin + ClopidogRel as Antithrombotic Treatment Following Transcatheter Aortic Valve Implantation With the Edwards SAPIEN XT Valve. A Randomized Pilot Study (the ARTE Trial)[NCT01559298]	Phase 4	178 participants (Actual)	Interventional	2012-03-31	Completed
A Phase III, Multicenter, Multinational, Randomized, Parallel Group, Double-blind Trial of Clopidogrel Versus Placebo in High-risk Patients Aged 45 Years and Older, at Risk of Atherothrombotic Events, and Who Are Receiving Background Therapy Including Low[NCT00050817]	Phase 3	15,603 participants (Actual)	Interventional	2002-10-31	Completed
"PGDT With the Hypotension Prediction Index to Reduce the Number and Duration of Intraoperative Hypotension and the Incidence of Renal Failure in Patients Undergoing Lung Surgery"[NCT04149314]		142 participants (Actual)	Interventional	2019-11-20	Completed
Clopidogrel and Proton Pump Inhibitors: A Propensity Score Adjusted Cohort Study to Examine a Possible Interaction: A CALIBER Study[NCT01231867]		24,471 participants (Actual)	Observational	2010-12-31	Completed
Effect of Acupuncture on Vascular Biomarkers and Psychological Well-Being of Women Undergoing In Vitro Fertilization (IVF)[NCT02591186]		60 participants (Actual)	Interventional	2015-11-01	Completed
Smartwatches for Detection of Atrial Fibrillation (AFib) in Secondary Prevention of Cryptogenic Stroke - WATCH AFib A Prospective, Intraindividual-controlled, Multicenter Clinical Study[NCT06005233]		400 participants (Anticipated)	Interventional	2024-01-31	Not yet recruiting
A Sequential Phase I - Phase II Pilot Study to Compare Cardiac Imaging Capabilities of ICE With TEE Followed by a Randomized Comparison of ICE Guided Cardioversion With Conventional Cardioversion Strategy in Patients With Atrial Fibrillation[NCT00281073]	Phase 1/Phase 2	95 participants (Actual)	Interventional	2005-03-31	Completed
[NCT00000500]	Phase 3	0 participants	Interventional	1981-09-30	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Count of participants and time from randomization to death by all cause were evaluated. Hazard ratios were calculated and reported as statistical analysis. (NCT01776424)
Timeframe: For each participants, death by any cause after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.

All-cause Mortality in LTOLE Part

Intervention	Participants (Count of Participants)
Rivaroxaban 2.5mg + Aspirin 100mg	313
Rivaroxaban 5mg + Aspirin Placebo	366
Rivaroxaban Placebo + Aspirin 100mg	378

Count of participants from COMPASS LTOLE initiation visit to death by all cause were evaluated. LTOLE: long-term open-lable extension (NCT01776424)
Timeframe: For each participants, death by any cause after COMPASS LTOLE initiation visit up until the the last LTOLE part contact date was considered. The mean time in follow-up until that date was 428 days.

The First Occurrence of MI, Ischemic Stroke, ALI, or Cardiovascular (CV) Death

Intervention	Participants (Count of Participants)
LTOLE Part: Rivaroxaban 2.5mg + Aspirin 100mg	282

Count of participants and time from randomization to the first occurrence of MI, ischemic stroke, ALI, or CV death were evaluated. Hazard ratios were calculated and reported as statistical analysis. (NCT01776424)
Timeframe: For each participant, the first occurrence of MI, ischemic stroke, ALI, or CV death after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.

The First Occurrence of Myocardial Infarction (MI), Ischemic Stroke, Acute Limb Ischemia (ALI), or Coronary Heart Disease (CHD) Death

Intervention	Participants (Count of Participants)
Rivaroxaban 2.5mg + Aspirin 100mg	389
Rivaroxaban 5mg + Aspirin Placebo	453
Rivaroxaban Placebo + Aspirin 100mg	516

Count of participants and time from randomization to the first occurrence of MI, ischemic stroke, ALI, or CHD death were evaluated. Hazard ratios were calculated and reported as statistical analysis. (NCT01776424)
Timeframe: For each participant, the first occurrence of MI, ALI, or CHD death after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.

The First Occurrence of the Composite Primary Efficacy Outcome, Myocardial Infarction (MI), Stroke, or Cardiovascular (CV) Death

Intervention	Participants (Count of Participants)
Rivaroxaban 2.5mg + Aspirin 100mg	329
Rivaroxaban 5mg + Aspirin Placebo	397
Rivaroxaban Placebo + Aspirin 100mg	450

Count of participants and time from randomization to the first occurrence of the composite primary efficacy outcome, MI, stroke, or CV death were evaluated. Hazard ratios were calculated and reported as statistical analysis. (NCT01776424)
Timeframe: For each participant, the first occurrence of the composite primary efficacy outcome after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.

The First Occurrence of the Composite Primary Efficacy Outcome, Myocardial Infarction (MI), Stroke, or Cardiovascular (CV) Death in LTOLE Part

Intervention	Participants (Count of Participants)
Rivaroxaban 2.5mg + Aspirin 100mg	379
Rivaroxaban 5mg + Aspirin Placebo	448
Rivaroxaban Placebo + Aspirin 100mg	496

Count of participants from COMPASS LTOLE initiation visit to the first occurrence of the composite primary efficacy outcome, MI, stroke, or CV death were evaluated. LTOLE: long-term open-lable extension (NCT01776424)
Timeframe: For each participant, the first occurrence of the composite primary efficacy outcome after from COMPASS LTOLE initiation visit up until last LTOLE part contact date was considered. The mean time in follow-up was 428 days.

The First Occurrence of the Primary Safety Outcome Major Bleeding Based on a Modification of the International Society on Thrombosis and Haemostasis (ISTH) Criteria

Intervention	Participants (Count of Participants)
LTOLE Part: Rivaroxaban 2.5mg + Aspirin 100mg	353

"Modified ISTH major bleeding is defined as: i) Fatal bleeding, or ii) Symptomatic bleeding in a critical area or organ, such as intraarticular, intracranial, intramuscular with compartment syndrome, intraocular, intraspinal, liver, pancreas, pericardial, respiratory, retroperitoneal, adrenal gland or kidney; or bleeding into the surgical site requiring reoperation, or iii) Bleeding leading to hospitalization (major bleeding also includes presentation to an acute care facility with discharge on the same day).~Count of participants and time from randomization to the first occurrence of the primary safety outcome major bleeding were evaluated. Hazard ratios were calculated and reported as statistical analysis." (NCT01776424)
Timeframe: For each participant, the first occurrence of modified ISTH major bleeding after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.

The First Occurrence of the Primary Safety Outcome Major Bleeding Based on a Modification of the International Society on Thrombosis and Haemostasis (ISTH) Criteria in LTOLE Part

Intervention	Participants (Count of Participants)
Rivaroxaban 2.5mg + Aspirin 100mg	288
Rivaroxaban 5mg + Aspirin Placebo	255
Rivaroxaban Placebo + Aspirin 100mg	170

"Modified ISTH major bleeding is defined as: i) Fatal bleeding, or ii) Symptomatic bleeding in a critical area or organ, such as intraarticular, intracranial, intramuscular with compartment syndrome, intraocular, intraspinal, liver, pancreas, pericardial, respiratory, retroperitoneal, adrenal gland or kidney; or bleeding into the surgical site requiring reoperation, or iii) Bleeding leading to hospitalization (major bleeding also includes presentation to an acute care facility with discharge on the same day).~Count of participants from COMPASS LTOLE initiation visit to the first occurrence of the primary safety outcome major bleeding was evaluated. LTOLE: long-term open-lable extension" (NCT01776424)
Timeframe: For each participant, the first occurrence of modified ISTH major bleeding from COMPASS LTOLE initiation visit up until 2 days after the last treatment in LTOLE part was considered. The mean time in follow-up was 421 days.

Composite of All-cause Mortality and Nonfatal MI

Composite of Ischemic Stroke, Myocardial Infarction, Death From Ischemic Vascular Causes, or Major Hemorrhage

Intervention	Participants (Count of Participants)
LTOLE Part: Rivaroxaban 2.5mg + Aspirin 100mg	138

Intervention	participants (Number)
Active Clonidine and Active ASA	173
Active Clonidine and Placebo ASA	194
Placebo Clonidine and Active ASA	178
Placebo Clonidine and Placebo ASA	161

Secondary efficacy outcome: Number of participants with ischemic stroke, myocardial infarction, death from ischemic vascular causes, or major hemorrhage (NCT00991029)
Timeframe: Up to 90 days

Composite of Ischemic Stroke, Myocardial Infarction, or Death From Ischemic Vascular Causes

Intervention	Participants (Count of Participants)
Clopidogrel	141
Placebo	167

Primary efficacy outcome: Number of Participants with Ischemic Stroke, Myocardial Infarction, or Death From Ischemic Vascular Causes (NCT00991029)
Timeframe: Up to 90 days

Death From Any Cause

Intervention	Participants (Count of Participants)
Clopidogrel	121
Placebo	160

Other safety outcome: Number of Participants with Death from any cause (NCT00991029)
Timeframe: up to 90 days

Death From Ischemic Vascular Causes

Intervention	Participants (Count of Participants)
Clopidogrel	18
Placebo	12

Secondary efficacy outcome: Number of participants with Death from ischemic vascular causes (NCT00991029)
Timeframe: Up to 90 days

Hemorrhagic Stroke

Intervention	Participants (Count of Participants)
Clopidogrel	6
Placebo	4

Other safety outcome: Number of participants with Hemorrhagic stroke (NCT00991029)
Timeframe: up to 90 days

Ischemic or Hemorrhagic Stroke

Intervention	Participants (Count of Participants)
Clopidogrel	5
Placebo	3

Secondary efficacy outcome: Number of participants with Ischemic or hemorrhagic stroke (NCT00991029)
Timeframe: Up to 90 days

Ischemic Stroke

Intervention	Participants (Count of Participants)
Clopidogrel	116
Placebo	156

Secondary efficacy outcome:Number of participants with Ischemic stroke (NCT00991029)
Timeframe: Up to 90 days

Major Hemorrhage

Intervention	Participants (Count of Participants)
Clopidogrel	112
Placebo	155

Primary safety outcome: Number of Participants with major hemorrhage (NCT00991029)
Timeframe: Up to 90 days

Major Hemorrhage Other Than Intracranial Hemorrhage

Intervention	Participants (Count of Participants)
Clopidogrel	23
Placebo	10

Other safety outcome: Number of Participants with Major hemorrhage other than intracranial hemorrhage (NCT00991029)
Timeframe: up to 90 days

Minor Hemorrhage

Intervention	Participants (Count of Participants)
Clopidogrel	17
Placebo	7

Other safety outcome:Number of Participants with Minor hemorrhage (NCT00991029)
Timeframe: up to 90 days

Myocardial Infarction

Intervention	Participants (Count of Participants)
Clopidogrel	40
Placebo	13

Secondary efficacy outcome: Number of participants with Myocardial infarction (NCT00991029)
Timeframe: Up to 90 days

Other Symptomatic Intracranial Hemorrhage

Intervention	Participants (Count of Participants)
Clopidogrel	10
Placebo	7

Other safety outcome: Number of participants with other symptomatic intracranial hemorrhage (NCT00991029)
Timeframe: up to 90 days

Symptomatic Intracerebral Hemorrhage

Intervention	Participants (Count of Participants)
Clopidogrel	2
Placebo	0

Other safety outcome: Number of participants with Symptomatic intracerebral hemorrhage (NCT00991029)
Timeframe: up to 90 days

Composite Outcome of Stroke, Myocardial Infarction (MI), or Vascular Death (Antiplatelet Comparison Only)

Intervention	Participants (Count of Participants)
Clopidogrel	2
Placebo	2

Number of patients with any of stroke, myocardial infarction, vascular death (NCT00153062)
Timeframe: time since randomization; follow-up period is 1.5 to 4.4 years

Composite Outcome of Stroke, Myocardial Infarction, Vascular Death, or New or Worsening Congestive Heart Failure (CHF) (Telmisartan vs. Placebo Only)

Intervention	Participants (Number)
Aspirin + Extended Release Dipyridamole	1333
Clopidogrel	1333

Number of patients with any of stroke, myocardial infarction, vascular death, or new or worsening congestive heart failure (NCT00153062)
Timeframe: time since randomization; follow-up period is 1.5 to 4.4 years

Number of Patients With First Recurrent Stroke of Any Type, Fatal or Nonfatal (Antiplatelet Comparison Only)

Intervention	Participants (Number)
Telmisartan	1367
Placebo	1463

(NCT00153062)
Timeframe: time since randomization; follow-up period is 1.5 to 4.4 years

Number of Patients With First Recurrent Stroke of Any Type, Fatal or Nonfatal (Telmisartan vs. Placebo Only)

Intervention	Participants (Number)
Aspirin + Extended Release Dipyridamole	916
Clopidogrel	898

(NCT00153062)
Timeframe: time since randomization; follow-up period is 1.5 to 4.4 years

Number of Patients With New Onset of Diabetes (Telmisartan vs. Placebo Only)

Adjudicated Major Bleedings

Intervention	Participants (Number)
Telmisartan	880
Placebo	934

Intervention	Participants (Number)
Telmisartan	125
Placebo	151

The number of participants with at least one major bleeding, validated by the Event Adjudication Committee are counted over the duration of the follow-up (including after permanent discontinuation of the study drug). (NCT00249873)
Timeframe: expected median follow-up of approximately 3 years

Death From Any Cause (Cardiovascular and Noncardiovascular)

Intervention	participants (Number)
Clopidogrel + ASA	251
Placebo + ASA	162

The considered event is death from any cause. The analysis is performed on the time from randomization to this event. Numbers of patients with the event over the duration of the follow-up are presented by arm group. (NCT00249873)
Timeframe: expected median follow-up of approximately 3 years

Occurrence of Stroke

Intervention	participants (Number)
Clopidogrel + ASA	825
Placebo + ASA	841

The event is the occurence of stroke (nonfatal or fatal, ischemic, hemorrhagic or of uncertain type) after validation of the Event Adjudication Committee . The analysis is performed on the time from randomization to the occurrence of this event. Numbers of patients with the event over the duration of the follow-up are presented by arm group. (NCT00249873)
Timeframe: expected median follow-up of approximately 3 years

First Occurence of Any Component of the Composite of Stroke, Non-Central Nervous System (Non-CNS) Systemic Embolism, Myocardial Infarction or Vascular Death as Per Adjudication

Intervention	participants (Number)
Clopidogrel + ASA	296
Placebo + ASA	408

"The primary event is the first occurence of any adjudicated component of the following cluster over the duration of follow-up :~stroke (nonfatal or fatal)~myocardial infarction (nonfatal or fatal)~non-CNS systemic embolism~vascular death~The primary efficacy analysis is performed on the time from randomization to this primary event. Numbers of patients with the composite event over the duration of the follow-up are presented by arm group." (NCT00249873)
Timeframe: expected median follow-up of approximately 3 years

Intervention	participants (Number)
	All components	- Myocardial Infarction (fatal or not)	- Stroke (fatal or not)	- Non-CNS systemic embolism	- Vascular death
Clopidogrel + ASA	832	84	285	50	413
Placebo + ASA	924	105	391	48	380

Article	Year
Ticagrelor for patients undergoing coronary artery bypass grafting: A meta-analysis of randomized controlled trials. Perfusion, 2023, Volume: 38, Issue:4 Topics: Aspirin; Coronary Artery Bypass; Graft Occlusion, Vascular; Hemorrhage; Humans; Platelet Aggregation	2023
Aspirin Resistance in Vascular Disease: A Review Highlighting the Critical Need for Improved Point-of-Care Testing and Personalized Therapy. International journal of molecular sciences, 2022, Sep-26, Volume: 23, Issue:19 Topics: Anticoagulants; Aspirin; Clopidogrel; Factor X; Humans; Platelet Aggregation Inhibitors; Point-of-Ca	2022
Extreme thrombocytosis in low-risk essential thrombocythemia: Retrospective review of vascular events and treatment strategies. American journal of hematology, 2021, 06-01, Volume: 96, Issue:6 Topics: Adolescent; Adult; Aspirin; Calreticulin; Disease-Free Survival; Erythrocyte Transfusion; Female; Fo	2021
[Ocular involvement in rheumatoid arthritis, connective tissue diseases and vasculitis]. Zeitschrift fur Rheumatologie, 2017, Volume: 76, Issue:8 Topics: Acute Disease; Adrenal Cortex Hormones; Arthritis, Rheumatoid; Aspirin; Collagen Diseases; Cross-Sec	2017
[Present and future of pharmaco-arteriothromboprophylaxis in clinical practice. Guidelines of Angiology Section of Slovak Medical Chamber]. Vnitrni lekarstvi, 2013, Volume: 59, Issue:12 Topics: Aspirin; Czech Republic; Drug Administration Schedule; Drug Therapy, Combination; Drugs, Investigati	2013
Antiplatelet treatment for prevention of cerebrovascular events in patients with vascular diseases: a systematic review and meta-analysis. Stroke, 2014, Volume: 45, Issue:2 Topics: Adenosine; Aged; Aspirin; Cerebral Hemorrhage; Cerebrovascular Disorders; Clopidogrel; Cohort Studie	2014
The Multifaceted Clinical Readouts of Platelet Inhibition by Low-Dose Aspirin. Journal of the American College of Cardiology, 2015, Jul-07, Volume: 66, Issue:1 Topics: Aspirin; Chemoprevention; Colorectal Neoplasms; Cyclooxygenase Inhibitors; Dementia, Vascular; Human	2015
Aspirin and heparin in pregnancy. Expert opinion on pharmacotherapy, 2015, Volume: 16, Issue:12 Topics: Anticoagulants; Aspirin; Female; Fibrinolytic Agents; Heparin; Humans; Pregnancy; Pregnancy Complica	2015
Spontaneous coronary artery dissection: the management dilemma continues. BMJ case reports, 2015, Aug-13, Volume: 2015 Topics: Adenosine; Adult; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Atorvastatin; Carbazol	2015
Spontaneous coronary artery dissection: Case report and review of the literature. Canadian family physician Medecin de famille canadien, 2016, Volume: 62, Issue:12 Topics: Acute Coronary Syndrome; Adrenergic beta-1 Receptor Antagonists; Adult; Aspirin; Atorvastatin; Clopi	2016
Management of type-2 diabetes with anti-platelet therapies: special reference to aspirin. Frontiers in bioscience (Scholar edition), 2011, 01-01, Volume: 3, Issue:1 Topics: Arachidonic Acid; Aspirin; Blood Platelets; Clopidogrel; Diabetes Mellitus, Type 2; Drug Resistance;	2011
Aspirin in stroke prevention in nonvalvular atrial fibrillation and stable vascular disease: an era of new anticoagulants. Expert review of cardiovascular therapy, 2012, Volume: 10, Issue:4 Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Guidelines as Topic; Humans; Stroke; Vascular Diseases	2012
Aspirin resistance. The Annals of pharmacotherapy, 2002, Volume: 36, Issue:10 Topics: Aspirin; Clinical Trials as Topic; Drug Resistance; Humans; Platelet Aggregation Inhibitors; Vascula	2002
Dipyridamole for preventing stroke and other vascular events in patients with vascular disease. The Cochrane database of systematic reviews, 2003, Issue:1 Topics: Anticoagulants; Aspirin; Cerebrovascular Disorders; Dipyridamole; Fibrinolytic Agents; Humans; Ische	2003
Prevention of vascular events in patients with atrial fibrillation: evidence, guidelines, and practice. Journal of cardiovascular electrophysiology, 2003, Volume: 14, Issue:9 Suppl Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Contraindications; Controlled Cl	2003
Clopidogrel's role in the management of atherosclerotic disease: a focus on acute coronary syndromes. Expert review of cardiovascular therapy, 2003, Volume: 1, Issue:4 Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Arteriosclerosis; Aspirin; Clinical Trials as Topi	2003
[Aspirin resistance]. Anadolu kardiyoloji dergisi : AKD = the Anatolian journal of cardiology, 2004, Volume: 4, Issue:1 Topics: Aspirin; Blood Platelets; Drug Resistance; Humans; Platelet Aggregation; Platelet Aggregation Inhibi	2004
Clinical effectiveness and cost-effectiveness of clopidogrel and modified-release dipyridamole in the secondary prevention of occlusive vascular events: a systematic review and economic evaluation. Health technology assessment (Winchester, England), 2004, Volume: 8, Issue:38 Topics: Aspirin; Clopidogrel; Cost-Benefit Analysis; Delayed-Action Preparations; Diarrhea; Dipyridamole; Dr	2004
Vascular complications of Fabry disease: enzyme replacement and other therapies. Acta paediatrica (Oslo, Norway : 1992). Supplement, 2005, Volume: 94, Issue:447 Topics: alpha-Galactosidase; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Aspirin; Blood Coagulati	2005
[Aspirin and primary prevention of vascular diseases in women]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2005, Volume: Suppl 15 Topics: Aspirin; Female; Fibrinolytic Agents; Humans; Primary Prevention; Treatment Outcome; Vascular Diseas	2005
Is clopidogrel cardiovascular medicine's double-edged sword? Circulation, 2006, Apr-04, Volume: 113, Issue:13 Topics: Aspirin; Clopidogrel; Coronary Artery Bypass, Off-Pump; Coronary Disease; Drug Therapy, Combination;	2006
Dipyridamole for preventing stroke and other vascular events in patients with vascular disease. The Cochrane database of systematic reviews, 2006, Apr-19, Issue:2 Topics: Anticoagulants; Aspirin; Cerebrovascular Disorders; Dipyridamole; Fibrinolytic Agents; Humans; Ische	2006
Vascular complications in Chuvash polycythemia. Seminars in thrombosis and hemostasis, 2006, Volume: 32, Issue:3 Topics: Aspirin; Humans; Phlebotomy; Polycythemia; Vascular Diseases	2006
[Resistance to acetylsalicylic acid and clopidogrel: current status]. Hamostaseologie, 2006, Volume: 26, Issue:3 Topics: Aspirin; Clopidogrel; Drug Monitoring; Drug Resistance; Humans; Platelet Aggregation; Platelet Aggre	2006
My health: whose responsibility? Low-dose aspirin and older people. Expert review of cardiovascular therapy, 2006, Volume: 4, Issue:5 Topics: Aged; Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Health; History, 19th Century; Hist	2006
Antiplatelet therapy for the prevention of recurrent stroke and other serious vascular events: a review of the clinical trial data and guidelines. Current medical research and opinion, 2007, Volume: 23, Issue:6 Topics: Aspirin; Clinical Trials as Topic; Drug Therapy, Combination; Guidelines as Topic; Humans; Ischemic	2007
Dipyridamole for preventing stroke and other vascular events in patients with vascular disease. The Cochrane database of systematic reviews, 2007, Jul-18, Issue:3 Topics: Anticoagulants; Aspirin; Cerebrovascular Disorders; Dipyridamole; Fibrinolytic Agents; Humans; Ische	2007
Response variability to aspirin as assessed by the platelet function analyzer (PFA)-100. A systematic review. Thrombosis and haemostasis, 2008, Volume: 99, Issue:1 Topics: Adult; Aged; Aspirin; Blood Platelets; Diabetes Mellitus, Type 2; Drug Monitoring; Drug Tolerance; E	2008
Risk factors for gastrointestinal complications in aspirin users: review of clinical and experimental data. Digestive diseases and sciences, 2008, Volume: 53, Issue:10 Topics: Alcohol Drinking; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Humans; Risk Factors; Smoking; S	2008
Don't add aspirin for associated stable vascular disease in a patient with atrial fibrillation receiving anticoagulation. BMJ (Clinical research ed.), 2008, Mar-15, Volume: 336, Issue:7644 Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Humans; Platelet Aggregation Inhibitors; Vascular Dise	2008
Meta-analysis of the efficacy and safety of clopidogrel plus aspirin as compared to antiplatelet monotherapy for the prevention of vascular events. The American journal of cardiology, 2008, Apr-01, Volume: 101, Issue:7 Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Humans; Male; Platelet Aggregation Inhibito	2008
Aspirin, clopidogrel, and warfarin: is the combination appropriate and effective or inappropriate and too dangerous? The Annals of pharmacotherapy, 2008, Volume: 42, Issue:6 Topics: Anticoagulants; Aspirin; Clinical Trials as Topic; Clopidogrel; Drug Interactions; Drug Therapy, Com	2008
Chemistry, measurement, and clinical significance of platelet specific proteins. Critical reviews in clinical laboratory sciences, 1982, Volume: 18, Issue:2 Topics: Aspirin; Beta-Globulins; beta-Thromboglobulin; Blood Coagulation; Blood Coagulation Factors; Blood P	1982
Arachidonate metabolism in vascular disorders. The Journal of clinical investigation, 1983, Volume: 72, Issue:5 Topics: Animals; Arachidonic Acid; Arachidonic Acids; Aspirin; Blood Platelets; Blood Vessels; Cyclic AMP; C	1983
Dipyridamole: a critical evaluation. Drug intelligence & clinical pharmacy, 1984, Volume: 18, Issue:11 Topics: Angina Pectoris; Aspirin; Blood Platelets; Cerebrovascular Disorders; Clinical Trials as Topic; Coro	1984
Prostacyclin. Progress in hemostasis and thrombosis, 1982, Volume: 6 Topics: Adenylyl Cyclases; Adult; Animals; Arteriosclerosis; Aspirin; Blood Platelet Disorders; Blood Platel	1982
Principles of thromboregulation: control of platelet reactivity in vascular disease. Advances in prostaglandin, thromboxane, and leukotriene research, 1995, Volume: 23 Topics: Animals; Aspirin; Blood Platelets; Eicosanoids; Endothelium, Vascular; Hemostasis; Homeostasis; Huma	1995
Efficacy and safety of different aspirin dosages on vascular diseases in high-risk patients. A metaregression analysis. The Online journal of current clinical trials, 1995, Mar-14, Volume: Doc No 174 Topics: Aspirin; Cerebral Hemorrhage; Cerebrovascular Disorders; Dose-Response Relationship, Drug; Gastroint	1995
The role of dipyridamole in the therapy of vascular disease. Geriatrics, 1993, Volume: 48, Issue:1 Topics: Animals; Aspirin; Coronary Artery Bypass; Dipyridamole; Graft Survival; Heart Valve Prosthesis; Huma	1993
Erythromelalgia and vascular complications in polycythemia vera. Seminars in thrombosis and hemostasis, 1997, Volume: 23, Issue:5 Topics: Aspirin; Erythromelalgia; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Polycy	1997
North of England evidence based guideline development project: guideline on the use of aspirin as secondary prophylaxis for vascular disease in primary care. North of England Aspirin Guideline Development Group. BMJ (Clinical research ed.), 1998, Apr-25, Volume: 316, Issue:7140 Topics: Angina Pectoris; Aspirin; Cardiovascular Diseases; Cerebrovascular Disorders; Consumer Product Safet	1998
The use of aspirin in polycythaemia vera and primary thrombocythaemia. Blood reviews, 1998, Volume: 12, Issue:1 Topics: Arachidonic Acid; Aspirin; Cyclooxygenase Inhibitors; Humans; Platelet Aggregation Inhibitors; Polyc	1998
Antiplatelet agents in the prevention of cardiovascular morbidity and mortality in older patients with vascular disease. Drugs & aging, 1999, Volume: 15, Issue:2 Topics: Aged; Aspirin; Cardiovascular Diseases; Clinical Trials as Topic; Clopidogrel; Female; Humans; Male;	1999
[The best of vascular pathology in 1999]. Archives des maladies du coeur et des vaisseaux, 2000, Volume: 93, Issue:1 Spec No Topics: Anti-Inflammatory Agents, Non-Steroidal; Aortic Aneurysm; Aspirin; ATP-Binding Cassette Transporters	2000
Aspirin and platelet-lowering agents for the prevention of vascular complications in essential thrombocythemia. Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, 1999, Volume: 5, Issue:4 Topics: Adolescent; Adult; Aged; Aspirin; Humans; Middle Aged; Platelet Aggregation Inhibitors; Platelet Cou	1999
Vascular drugs in the new millennium. Journal of the American College of Surgeons, 2000, Volume: 191, Issue:1 Topics: Abciximab; Animals; Anistreplase; Antibodies, Monoclonal; Anticoagulants; Aspirin; Chondroitin Sulfa	2000
Prostaglandins in circulatory disorders. Triangle; the Sandoz journal of medical science, 1979, Volume: 18, Issue:4 Topics: Angiotensin II; Antihypertensive Agents; Arachidonic Acids; Arteriosclerosis; Aspirin; Blood Platele	1979
Critical evaluation of platelet-inhibiting drugs in thrombotic disease. Progress in hematology, 1975, Volume: 9 Topics: Arteriosclerosis; Aspirin; Blood Platelets; Cerebrovascular Disorders; Clinical Trials as Topic; Clo	1975
Long-term antiplatelet therapy for the prevention of vascular disease. The Medical journal of Australia, 1991, Apr-01, Volume: 154, Issue:7 Topics: Aspirin; Cerebrovascular Disorders; Evaluation Studies as Topic; Humans; Long-Term Care; Myocardial	1991
[Acetylsalicylic acid of fish oil for the prevention of degenerative circulatory diseases?]. Deutsche medizinische Wochenschrift (1946), 1990, Jan-05, Volume: 115, Issue:1 Topics: Aspirin; Fatty Acids, Omega-3; Fish Oils; Humans; Myocardial Infarction; Vascular Diseases	1990
Pathological significance of the thromboxane-prostacyclin hypothesis. Journal of cardiovascular pharmacology, 1985, Volume: 7 Suppl 3 Topics: Animals; Arteriosclerosis; Aspirin; Blood Platelets; Blood Vessels; Epoprostenol; Humans; Prostaglan	1985
Noncoronary angioplasty. Radiology, 1989, Volume: 170, Issue:3 Pt 2 Topics: Angioplasty, Balloon; Aspirin; Constriction, Pathologic; Heparin; Humans; Nifedipine; Nitroglycerin;	1989
[Platelet function inhibitors in peripheral arteriopathies]. Recenti progressi in medicina, 1986, Volume: 77, Issue:4 Topics: Adrenal Cortex Hormones; Adrenergic alpha-Antagonists; Anti-Inflammatory Agents; Arachidonic Acid; A	1986
Primary prevention of vascular disease by aspirin. Lancet (London, England), 1988, May-14, Volume: 1, Issue:8594 Topics: Adult; Aged; Aged, 80 and over; Aspirin; Clinical Trials as Topic; Follow-Up Studies; Humans; Male;	1988
Antiplatelet drugs in the management of patients with thrombotic disorders. Seminars in thrombosis and hemostasis, 1986, Volume: 12, Issue:2 Topics: Arterial Occlusive Diseases; Arteriosclerosis; Aspirin; Blood Coagulation Disorders; Blood Platelets	1986
[Acetylsalicylic acid therapy in vascular diseases]. Deutsche medizinische Wochenschrift (1946), 1988, Jul-15, Volume: 113, Issue:28-29 Topics: Arterial Occlusive Diseases; Aspirin; Cerebrovascular Disorders; Clinical Trials as Topic; Coronary	1988
Indications for use of aspirin and corticosteroid hormones in the treatment of canine heartworm disease. Seminars in veterinary medicine and surgery (small animal), 1987, Volume: 2, Issue:1 Topics: Adrenal Cortex Hormones; Animals; Aspirin; Dirofilariasis; Dog Diseases; Dogs; Lung Diseases, Parasi	1987
Platelet suppressive therapy in clinical medicine. British journal of haematology, 1985, Volume: 60, Issue:4 Topics: Aspirin; Blood Platelets; Cerebrovascular Disorders; Coronary Disease; Female; Heart Valve Prosthesi	1985
A critical reappraisal of juvenile rheumatoid arthritis. Clinical orthopaedics and related research, 1971, Volume: 74 Topics: Agammaglobulinemia; Arthritis, Juvenile; Aspirin; Cardiomegaly; Child; Child, Preschool; Chloroquine	1971
Bleeding in uremia. The Medical clinics of North America, 1972, Volume: 56, Issue:1 Topics: Adenine Nucleotides; Aspirin; Blood Coagulation Disorders; Blood Platelet Disorders; Capillary Fragi	1972
Rheumatoid arthritis. JAMA, 1973, Apr-30, Volume: 224, Issue:5 Suppl Topics: Antigen-Antibody Reactions; Arthritis, Juvenile; Arthritis, Rheumatoid; Aspirin; Biopsy; Chloroquine	1973
Allergy in adverse drug reactions. Seminars in drug treatment, 1973,Spring, Volume: 2, Issue:4 Topics: Abnormalities, Drug-Induced; Adult; Age Factors; Aged; Anemia, Aplastic; Anemia, Hemolytic; Anemia,	1973
[Polymyalgia rheumatica (comprehensive review)]. Fysiatricky a reumatologicky vestnik, 1973, Volume: 51, Issue:4 Topics: Age Factors; Aspirin; Blood Protein Electrophoresis; Blood Sedimentation; Diagnosis, Differential; G	1973

Article	Year
Vasodilator response to galvanic current stimulation of the skin accurately detects acetylsalicylic acid intake: A study in 400 vascular patients. Atherosclerosis, 2018, Volume: 270 Topics: Aged; Aspirin; Body Mass Index; Cardiovascular Agents; Drug Monitoring; Female; Galvanic Skin Respon	2018
[The COMPASS study]. Giornale italiano di cardiologia (2006), 2018, Volume: 19, Issue:1 Topics: Aspirin; Atherosclerosis; Double-Blind Method; Drug Therapy, Combination; Factor Xa Inhibitors; Fibr	2018
Effect of aspirin in vascular surgery in patients from a randomized clinical trial (POISE-2). The British journal of surgery, 2018, Volume: 105, Issue:12 Topics: Aged; Aspirin; Constriction, Pathologic; Female; Humans; Male; Myocardial Infarction; Perioperative	2018
Impact of adding aspirin to beta-blocker and statin in high-risk patients undergoing major vascular surgery. Annals of vascular surgery, 2013, Volume: 27, Issue:4 Topics: Adrenergic beta-Antagonists; Aged; Aspirin; Dose-Response Relationship, Drug; Drug Therapy, Combinat	2013
Triflusal and aspirin in the secondary prevention of atherothrombotic ischemic stroke: a very long-term follow-up. Cerebrovascular diseases (Basel, Switzerland), 2014, Volume: 37, Issue:3 Topics: Aged; Aspirin; Brain Ischemia; Dyspepsia; Female; Follow-Up Studies; Hemorrhage; Humans; Incidence;	2014
Comparison of integrated traditional Chinese and western medicine therapy on vascular cognitive impairment with no dementia. Genetics and molecular research : GMR, 2015, May-11, Volume: 14, Issue:2 Topics: Aged; Aspirin; Cerebellum; Cognition Disorders; Dementia; Drugs, Chinese Herbal; Female; Ginkgo bilo	2015
Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. The New England journal of medicine, 2008, Sep-18, Volume: 359, Issue:12 Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Brain Ischemia;	2008
Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. The New England journal of medicine, 2008, Sep-18, Volume: 359, Issue:12 Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Brain Ischemia;	2008
Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. The New England journal of medicine, 2008, Sep-18, Volume: 359, Issue:12 Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Brain Ischemia;	2008
Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. The New England journal of medicine, 2008, Sep-18, Volume: 359, Issue:12 Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Brain Ischemia;	2008
Effect of clopidogrel added to aspirin in patients with atrial fibrillation. The New England journal of medicine, 2009, May-14, Volume: 360, Issue:20 Topics: Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Emb	2009
Effect of clopidogrel added to aspirin in patients with atrial fibrillation. The New England journal of medicine, 2009, May-14, Volume: 360, Issue:20 Topics: Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Emb	2009
Effect of clopidogrel added to aspirin in patients with atrial fibrillation. The New England journal of medicine, 2009, May-14, Volume: 360, Issue:20 Topics: Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Emb	2009
Effect of clopidogrel added to aspirin in patients with atrial fibrillation. The New England journal of medicine, 2009, May-14, Volume: 360, Issue:20 Topics: Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Emb	2009
Effect of clopidogrel added to aspirin in patients with atrial fibrillation. The New England journal of medicine, 2009, May-14, Volume: 360, Issue:20 Topics: Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Emb	2009
Effect of clopidogrel added to aspirin in patients with atrial fibrillation. The New England journal of medicine, 2009, May-14, Volume: 360, Issue:20 Topics: Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Emb	2009
Effect of clopidogrel added to aspirin in patients with atrial fibrillation. The New England journal of medicine, 2009, May-14, Volume: 360, Issue:20 Topics: Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Emb	2009
Effect of clopidogrel added to aspirin in patients with atrial fibrillation. The New England journal of medicine, 2009, May-14, Volume: 360, Issue:20 Topics: Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Emb	2009
Effect of clopidogrel added to aspirin in patients with atrial fibrillation. The New England journal of medicine, 2009, May-14, Volume: 360, Issue:20 Topics: Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Emb	2009
Rationale, design, and baseline data of the Japanese Primary Prevention Project (JPPP)-a randomized, open-label, controlled trial of aspirin versus no aspirin in patients with multiple risk factors for vascular events. American heart journal, 2010, Volume: 159, Issue:3 Topics: Aged; Aged, 80 and over; Asian People; Aspirin; Cohort Studies; Diabetes Mellitus; Dose-Response Rel	2010
Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHAR Circulation, 2010, Jun-15, Volume: 121, Issue:23 Topics: Aged; Aspirin; Clopidogrel; Disease Management; Double-Blind Method; Drug Therapy, Combination; Fema	2010
A randomized trial of aspirin at clinically relevant doses and nitric oxide formation in humans. Journal of cardiovascular pharmacology and therapeutics, 2010, Volume: 15, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Aspirin; Biomarkers; Cardiovascular Diseases; Female; Humans; Male;	2010
Aspirin dosage and thromboxane synthesis in patients with vascular disease. Pharmacotherapy, 2003, Volume: 23, Issue:5 Topics: Aged; Aspirin; Cross-Over Studies; Dose-Response Relationship, Drug; Female; Humans; Male; Platelet	2003
Assessing aspirin responsiveness in subjects with multiple risk factors for vascular disease with a rapid platelet function analyzer. Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 2004, Volume: 15, Issue:4 Topics: Adult; Aspirin; Drug Resistance; Female; Humans; Male; Middle Aged; Platelet Aggregation; Platelet A	2004
ESPRIT study design and outcomes--a critical appraisal. Current medical research and opinion, 2007, Volume: 23, Issue:2 Topics: Aspirin; Biomarkers; Brain Ischemia; Dipyridamole; Drug Therapy, Combination; Fibrinolytic Agents; H	2007
Dipyridamole: a critical evaluation. Drug intelligence & clinical pharmacy, 1984, Volume: 18, Issue:11 Topics: Angina Pectoris; Aspirin; Blood Platelets; Cerebrovascular Disorders; Clinical Trials as Topic; Coro	1984
Plasma factor and platelet sensitivity to prostacyclin in patients with peripheral vascular disease before and after treatment with a combination of a cyclooxygenase and a phosphodiesterase inhibitor. Prostaglandins, leukotrienes, and medicine, 1984, Volume: 15, Issue:2 Topics: Aspirin; Blood Platelets; Clinical Trials as Topic; Cyclooxygenase Inhibitors; Dipyridamole; Drug Th	1984
The Warfarin-Aspirin Symptomatic Intracranial Disease Study. Neurology, 1995, Volume: 45, Issue:8 Topics: Animals; Aspirin; Cerebral Angiography; Cerebral Hemorrhage; Cerebrovascular Disorders; Cohort Studi	1995
Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group. Lancet (London, England), 1993, Nov-20, Volume: 342, Issue:8882 Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Double-Blind Method;	1993
Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group. Lancet (London, England), 1993, Nov-20, Volume: 342, Issue:8882 Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Double-Blind Method;	1993
Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group. Lancet (London, England), 1993, Nov-20, Volume: 342, Issue:8882 Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Double-Blind Method;	1993
Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group. Lancet (London, England), 1993, Nov-20, Volume: 342, Issue:8882 Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Double-Blind Method;	1993
Prospective study of moderate alcohol consumption and risk of peripheral arterial disease in US male physicians. Circulation, 1997, Feb-04, Volume: 95, Issue:3 Topics: Adult; Alcohol Drinking; Arteries; Aspirin; beta Carotene; Cardiovascular Diseases; Double-Blind Met	1997
Diabetes mellitus, hypercholesterolemia, and hypertension but not vascular disease per se are associated with persistent platelet activation in vivo. Evidence derived from the study of peripheral arterial disease. Circulation, 1997, Jul-01, Volume: 96, Issue:1 Topics: Adult; Aged; Aspirin; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Female; Follow-Up Studies;	1997
The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial programme; rationale, design and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular disease. European heart journal, 2000, Volume: 21, Issue:24 Topics: Angina, Unstable; Aspirin; Clopidogrel; Humans; Meta-Analysis as Topic; Platelet Aggregation Inhibit	2000
Anticoagulant (fluindione)-aspirin combination in patients with high-risk atrial fibrillation. A randomized trial (Fluindione, Fibrillation Auriculaire, Aspirin et Contraste Spontané; FFAACS). Cerebrovascular diseases (Basel, Switzerland), 2001, Volume: 12, Issue:3 Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Dose-Response Relationship	2001
[Venous diseases. Controlled study using an antivaricose preparation Bayro-Vas]. Die Medizinische Welt, 1975, Apr-25, Volume: 26, Issue:17 Topics: Adolescent; Adult; Aged; Aspirin; Clinical Trials as Topic; Drug Combinations; Drug Evaluation; Esci	1975
Critical evaluation of platelet-inhibiting drugs in thrombotic disease. Progress in hematology, 1975, Volume: 9 Topics: Arteriosclerosis; Aspirin; Blood Platelets; Cerebrovascular Disorders; Clinical Trials as Topic; Clo	1975
A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. The New England journal of medicine, 1991, 10-31, Volume: 325, Issue:18 Topics: Aged; Aspirin; Cerebrovascular Disorders; Double-Blind Method; Female; Follow-Up Studies; Humans; Is	1991
[Platelet function inhibitors in peripheral arteriopathies]. Recenti progressi in medicina, 1986, Volume: 77, Issue:4 Topics: Adrenal Cortex Hormones; Adrenergic alpha-Antagonists; Anti-Inflammatory Agents; Arachidonic Acid; A	1986
Primary prevention of vascular disease by aspirin. Lancet (London, England), 1988, May-14, Volume: 1, Issue:8594 Topics: Adult; Aged; Aged, 80 and over; Aspirin; Clinical Trials as Topic; Follow-Up Studies; Humans; Male;	1988
[Acetylsalicylic acid therapy in vascular diseases]. Deutsche medizinische Wochenschrift (1946), 1988, Jul-15, Volume: 113, Issue:28-29 Topics: Arterial Occlusive Diseases; Aspirin; Cerebrovascular Disorders; Clinical Trials as Topic; Coronary	1988
Aspirin, indomethacin and dazoxiben do not affect the fibrinolytic activation induced by venous occlusion. Thrombosis research, 1985, Oct-15, Volume: 40, Issue:2 Topics: Aspirin; Double-Blind Method; Fibrinolysis; Humans; Imidazoles; Indomethacin; Male; Prostaglandins;	1985

Article	Year
The First Year of the COVID-19 Pandemic: Changes in Preventive Services in Community Health Centers. American journal of preventive medicine, 2023, Volume: 64, Issue:2 Topics: Aspirin; Colorectal Neoplasms; Community Health Centers; COVID-19; Early Detection of Cancer; Female	2023
Progressive arteriopathy with vasospasm in focal cerebral arteriopathy in childhood: a case report. BMC neurology, 2023, Jul-24, Volume: 23, Issue:1 Topics: Aspirin; Cerebrovascular Disorders; Child; Constriction, Pathologic; Female; Humans; Middle Cerebral	2023
Aspirin for primary prevention of CVD in CKD: where do we stand? The British journal of general practice : the journal of the Royal College of General Practitioners, 2019, Volume: 69, Issue:689 Topics: Aspirin; Cardiovascular Diseases; Humans; Primary Prevention; Renal Insufficiency, Chronic; Secondar	2019
Intense exercise may not be so benign: chest pain in a young athletic woman may be spontaneous coronary artery dissection (SCAD). BMJ case reports, 2020, Apr-06, Volume: 13, Issue:4 Topics: Adult; Aspirin; Chest Pain; Clopidogrel; Coronary Angiography; Coronary Vessel Anomalies; Coronary V	2020
[Mortality benefit with different antithrombotic therapies in patients with stable vascular disease: from pathophysiology to the clinical impact in the real world. The COMPASS study]. Giornale italiano di cardiologia (2006), 2020, Volume: 21, Issue:7 Topics: Anticoagulants; Aspirin; Drug Therapy, Combination; Humans; Platelet Aggregation Inhibitors; Randomi	2020
Conservative management of spontaneous coronary artery dissection: a case report. The Pan African medical journal, 2020, Volume: 36 Topics: Adrenergic beta-Antagonists; Adult; Aspirin; Computed Tomography Angiography; Conservative Treatment	2020
Letter by McCaw et al Regarding Article, "The COMPASS Trial: Net Clinical Benefit of Low-Dose Rivaroxaban Plus Aspirin as Compared With Aspirin in Patients With Chronic Vascular Disease". Circulation, 2021, 01-05, Volume: 143, Issue:1 Topics: Aspirin; Factor Xa Inhibitors; Humans; Platelet Aggregation Inhibitors; Rivaroxaban; Vascular Diseas	2021
Response by Fox to Letter Regarding Article, "The COMPASS Trial: Net Clinical Benefit of Low-Dose Rivaroxaban Plus Aspirin as Compared With Aspirin in Patients With Chronic Vascular Disease". Circulation, 2021, 01-05, Volume: 143, Issue:1 Topics: Aspirin; Factor Xa Inhibitors; Humans; Platelet Aggregation Inhibitors; Rivaroxaban; Vascular Diseas	2021
Age-specific risks, severity, time course, and outcome of bleeding on long-term antiplatelet treatment after vascular events: a population-based cohort study. Lancet (London, England), 2017, 07-29, Volume: 390, Issue:10093 Topics: Age Distribution; Age Factors; Aged; Aged, 80 and over; Aspirin; Cohort Studies; England; Female; Ga	2017
Non-invasive management of post-partum spontaneous left main coronary artery dissection using cardiac computed tomography angiography. European heart journal. Cardiovascular Imaging, 2017, 10-01, Volume: 18, Issue:10 Topics: Adult; Aspirin; Bisoprolol; Cesarean Section; Clopidogrel; Computed Tomography Angiography; Conserva	2017
A soccer mom with chest pain: Spontaneous coronary artery dissection in a young woman. Rhode Island medical journal (2013), 2017, 08-01, Volume: 100, Issue:8 Topics: Aspirin; Cardiac Catheterization; Chest Pain; Coronary Angiography; Coronary Vessel Anomalies; Diagn	2017
Early aspirin initiation following heart transplantation is associated with reduced risk of allograft vasculopathy during long-term follow-up. Clinical transplantation, 2017, Volume: 31, Issue:12 Topics: Adult; Allografts; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Female; Follow-Up Studies; Graf	2017
Plasma miR-142 predicts major adverse cardiovascular events as an intermediate biomarker of dual antiplatelet therapy. Acta pharmacologica Sinica, 2019, Volume: 40, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Female; H	2019
Anti-thrombotic options for secondary prevention in patients with chronic atherosclerotic vascular disease: what does COMPASS add? European heart journal, 2019, 05-07, Volume: 40, Issue:18 Topics: Aspirin; Atherosclerosis; Chronic Disease; Clinical Trials as Topic; Death; Drug Therapy, Combinatio	2019
Spontaneous Coronary Artery Dissection in the Postoperative Period: A Case Report. A&A practice, 2019, Aug-01, Volume: 13, Issue:3 Topics: Adult; Aspirin; Bisoprolol; Clopidogrel; Coronary Angiography; Coronary Vessel Anomalies; Female; He	2019
Renal Dysfunction: The Wake-Up Alarm for Chronic Vascular Disease. Journal of the American College of Cardiology, 2019, 05-14, Volume: 73, Issue:18 Topics: Aspirin; Factor Xa Inhibitors; Humans; Kidney Diseases; Rivaroxaban; Vascular Diseases	2019
A Woman With Multiparity Experiencing Chest Pain in Her Early 60s. JAMA cardiology, 2019, 07-01, Volume: 4, Issue:7 Topics: Adrenergic beta-Antagonists; Aspirin; Chest Pain; Clopidogrel; Coronary Vessel Anomalies; Drug Thera	2019
Post-filler vascular occlusion: a cautionary tale and emphasis for early intervention. Journal of drugs in dermatology : JDD, 2013, Volume: 12, Issue:10 Topics: Adult; Aspirin; Cosmetic Techniques; Female; Humans; Hyaluronic Acid; Hyaluronoglucosaminidase; Hype	2013
Tips for GP trainees working in vascular surgery. The British journal of general practice : the journal of the Royal College of General Practitioners, 2014, Volume: 64, Issue:619 Topics: Anticholesteremic Agents; Aspirin; Blood Pressure; Clinical Competence; Clopidogrel; Education, Medi	2014
Spontaneous coronary artery dissection: a complete resolution with medical treatment. BMJ case reports, 2014, Oct-15, Volume: 2014 Topics: Adult; Aspirin; Clopidogrel; Coronary Angiography; Coronary Vessel Anomalies; Fibrinolytic Agents; H	2014
Spontaneous coronary artery dissection in a parturient with Nail-Patella syndrome. International journal of obstetric anesthesia, 2015, Volume: 24, Issue:1 Topics: Adult; Anti-Arrhythmia Agents; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Antidiuretic	2015
Spontaneous coronary artery dissection in the presence of myocardial bridge causing myocardial infarction: an insight into mechanism. International journal of cardiology, 2016, Mar-01, Volume: 206 Topics: Adult; Aspirin; Atorvastatin; Clopidogrel; Coronary Angiography; Coronary Vessel Anomalies; Female;	2016
Isolated septal myocardial infarction due to spontaneous coronary artery dissection. International journal of cardiology, 2016, Jun-01, Volume: 212 Topics: Adrenergic beta-Antagonists; Aspirin; Coronary Vessel Anomalies; Diagnosis, Differential; Drug Thera	2016
Assessment of Vascular Disease Prevention Practices in Urban Women. Journal of women's health (2002), 2016, Volume: 25, Issue:8 Topics: Aged; Aspirin; Female; Fibrinolytic Agents; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors;	2016
Venous leg ulcer study needs more participants. Nursing New Zealand (Wellington, N.Z. : 1995), 2016, Volume: 22, Issue:3 Topics: Aspirin; Clinical Trials as Topic; Dose-Response Relationship, Drug; Humans; Leg Ulcer; Vascular Dis	2016
Aspirin for cancer is no mere antiplatelet prototype. There is potential in its ancient roots. Medical hypotheses, 2016, Volume: 94 Topics: Animals; Aspirin; Blood Platelets; Colorectal Neoplasms; Cyclooxygenase Inhibitors; Gastrointestinal	2016
Spontaneous coronary artery dissection in a young woman with polycystic ovarian syndrome. The American journal of emergency medicine, 2017, Volume: 35, Issue:6 Topics: Acute Coronary Syndrome; Adenosine; Adult; Aspirin; Chest Pain; Coronary Angiography; Coronary Vesse	2017
Lack of association between aspirin responsiveness and seven candidate gene haplotypes in patients with symptomatic vascular disease. Thrombosis and haemostasis, 2009, Volume: 101, Issue:1 Topics: Adenosine Diphosphate; Aged; Aged, 80 and over; Aspirin; Cohort Studies; Cyclooxygenase 1; Drug Resi	2009
[Increased intima-media thickness: an indication for aspirin?]. Deutsche medizinische Wochenschrift (1946), 2009, Volume: 134, Issue:34-35 Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Carotid Arteries; Humans; Male; Middle Aged; Prima	2009
Aspirin in the primary prevention of vascular disease. Lancet (London, England), 2009, Sep-12, Volume: 374, Issue:9693 Topics: Anti-Ulcer Agents; Aspirin; Barrett Esophagus; Drug Therapy, Combination; Evidence-Based Medicine; H	2009
Aspirin in the primary prevention of vascular disease. Lancet (London, England), 2009, Sep-12, Volume: 374, Issue:9693 Topics: Aspirin; Evidence-Based Medicine; Humans; Meta-Analysis as Topic; Myocardial Infarction; Platelet Ag	2009
Aspirin in the primary prevention of vascular disease. Lancet (London, England), 2009, Sep-12, Volume: 374, Issue:9693 Topics: Aspirin; Humans; Meta-Analysis as Topic; Platelet Aggregation Inhibitors; Primary Prevention; Resear	2009
Clopidogrel plus aspirin in atrial fibrillation. The New England journal of medicine, 2009, Sep-24, Volume: 361, Issue:13 Topics: Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; Embolism; Humans; Myocardial I	2009
Strategy to prevent recurrent portal vein stenosis following interventional radiology in pediatric liver transplantation. Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 2010, Volume: 16, Issue:3 Topics: Adolescent; Adult; Anticoagulants; Aspirin; Catheterization; Child; Child, Preschool; Constriction,	2010
Role of dual antiplatelet therapy in symptomatic patients with established vascular disease: putting the CHARISMA trial into therapeutic perspective. Cardiovascular drugs and therapy, 2010, Volume: 24, Issue:3 Topics: Aspirin; Clopidogrel; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Randomized Controlled Tri	2010
Knowledge, attitudes and current practice of Jordanian family physicians about prescribing aspirin in primary and secondary prevention of vascular diseases: a self-reported survey. European journal of cardiovascular nursing, 2012, Volume: 11, Issue:1 Topics: Adult; Aspirin; Comorbidity; Family Practice; Female; Health Care Surveys; Health Knowledge, Attitud	2012
Enhanced functional stability of plasminogen activator inhibitor-1 in patients with livedoid vasculopathy. Journal of thrombosis and thrombolysis, 2011, Volume: 32, Issue:1 Topics: Adolescent; Adult; Aspirin; Dipyridamole; Female; Fibrinolysis; Humans; Male; Plasminogen Activator	2011
Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (NICE technology appraisal guidance 90). Heart (British Cardiac Society), 2011, Volume: 97, Issue:7 Topics: Aspirin; Clopidogrel; Constriction, Pathologic; Delayed-Action Preparations; Dipyridamole; Drugs, Ge	2011
Aspirin about 50 years of age for the primary prevention of disease? Perspectives in public health, 2011, Volume: 131, Issue:2 Topics: Aspirin; Humans; Meta-Analysis as Topic; Middle Aged; Neoplasms; Primary Prevention; Vascular Diseas	2011
Prospective cohort study of gastrointestinal complications and vascular diseases in patients taking aspirin: rationale and design of the MAGIC Study. Cardiovascular drugs and therapy, 2011, Volume: 25, Issue:6 Topics: Aspirin; Cohort Studies; Epidemiologic Research Design; Gastrointestinal Diseases; Humans; Japan; Pl	2011
The MAGIC Study and the gastrointestinal effects of low-dose aspirin : editorial to: "Prospective cohort study of gastrointestinal complications and vascular diseases in patients taking aspirin: rationale and design of the MAGIC Study" by H. Origasa et al Cardiovascular drugs and therapy, 2011, Volume: 25, Issue:6 Topics: Aspirin; Epidemiologic Research Design; Gastrointestinal Diseases; Humans; Platelet Aggregation Inhi	2011
Level of systolic blood pressure within the normal range and risk of recurrent stroke. JAMA, 2011, Nov-16, Volume: 306, Issue:19 Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Blood Pressure;	2011
Level of systolic blood pressure within the normal range and risk of recurrent stroke. JAMA, 2011, Nov-16, Volume: 306, Issue:19 Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Blood Pressure;	2011
Level of systolic blood pressure within the normal range and risk of recurrent stroke. JAMA, 2011, Nov-16, Volume: 306, Issue:19 Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Blood Pressure;	2011
Level of systolic blood pressure within the normal range and risk of recurrent stroke. JAMA, 2011, Nov-16, Volume: 306, Issue:19 Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Blood Pressure;	2011
The combined use of aspirin, a statin, and blood pressure-lowering agents (polypill components) in clinical practice in patients with vascular diseases or type 2 diabetes mellitus. European journal of preventive cardiology, 2013, Volume: 20, Issue:5 Topics: Adult; Aged; Antihypertensive Agents; Aspirin; Diabetes Mellitus, Type 2; Drug Combinations; Drug Th	2013
Clopidogrel and interaction with proton pump inhibitors: comparison between cohort and within person study designs. BMJ (Clinical research ed.), 2012, Jul-10, Volume: 345 Topics: Aspirin; Clopidogrel; Cohort Studies; Data Collection; Drug Interactions; Humans; Multivariate Analy	2012
Long-term risk of vascular events after peripheral bypass surgery. A cohort study. Thrombosis and haemostasis, 2012, Volume: 108, Issue:3 Topics: Administration, Oral; Aged; Aged, 80 and over; Amputation, Surgical; Anticoagulants; Aspirin; Blood	2012
Platelets in vascular disease. Clinical hemorheology and microcirculation, 2013, Volume: 53, Issue:1-2 Topics: Aspirin; Atherosclerosis; Blood Platelets; Clopidogrel; Hemostasis; Humans; Plaque, Atherosclerotic;	2013
Current controversies in prenatal diagnosis 4: pregnancy complications due to placental vascular disease (pre-eclampsia, FGR): are we ready for prevention? Prenatal diagnosis, 2013, Volume: 33, Issue:1 Topics: Aspirin; Calcium; Female; Fetal Growth Retardation; Gestational Age; Humans; Placenta; Placenta Dise	2013
Thrombotic complications related to discontinuation of warfarin and aspirin therapy perioperatively for cutaneous operation. Journal of the American Academy of Dermatology, 2003, Volume: 48, Issue:2 Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Female; Humans; Ischemic Attack, Transient; Male;	2003
Aspirin resistance: a new independent predictor of vascular events? Journal of the American College of Cardiology, 2003, Mar-19, Volume: 41, Issue:6 Topics: Aspirin; Blood Platelets; Cardiovascular Diseases; Drug Resistance; Fibrinolytic Agents; Humans; Out	2003
Hemorrhagic diathesis with increased capillary fragility caused by salicylate therapy. The American journal of the medical sciences, 1956, Volume: 231, Issue:4 Topics: Aspirin; Capillaries; Capillary Fragility; Hemorrhage; Hemorrhagic Disorders; Humans; Salicylates; V	1956
[CLINICAL USE OF TH-2152. APROPOS OF 57 CASES]. Lyon medical, 1964, May-10, Volume: 211 Topics: Analgesia; Aspirin; Carbonates; Fever; Headache; Humans; Infections; Neoplasms; Neuralgia; Pain Mana	1964
CUTANEOUS MANIFESTATIONS OF SYSTEMIC LUPUS ERYTHEMATOSUS. Archives of dermatology, 1964, Volume: 90 Topics: Adrenal Cortex Hormones; Alopecia; Anti-Bacterial Agents; Antimalarials; Aspirin; Blister; Drug Erup	1964
Prophylactic aspirin use in the adult general population. Journal of public health medicine, 2003, Volume: 25, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cross-Sectional Studies; Drug Utilization; Female; Humans;	2003
Consensus statement for the prevention of vascular disease. Australian family physician, 2004, Volume: 33, Issue:4 Topics: Aged; Aspirin; Atrial Fibrillation; Australia; Diabetes Complications; Diabetes Mellitus; Family Pra	2004
Clopidogrel versus aspirin for secondary prophylaxis of vascular events: a cost-effectiveness analysis. The American journal of medicine, 2004, Jun-15, Volume: 116, Issue:12 Topics: Aspirin; Clopidogrel; Cost-Benefit Analysis; Fibrinolytic Agents; Humans; Markov Chains; Middle Aged	2004
Aspirin in the treatment of vascular diseases. Lancet (London, England), 1949, Dec-24, Volume: 2, Issue:6591 Topics: Aspirin; Blood Vessels; Humans; Vascular Diseases	1949
What next for low dose aspirin? Journal of epidemiology and community health, 2005, Volume: 59, Issue:1 Topics: Age Factors; Aspirin; Drug Administration Schedule; Female; Fibrinolytic Agents; Health Education; H	2005
Endoscopy in asymptomatic minidose aspirin consumers. Digestive diseases and sciences, 2005, Volume: 50, Issue:1 Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Dose-Response Relationshi	2005
Modelling the long term cost effectiveness of clopidogrel for the secondary prevention of occlusive vascular events in the UK. Current medical research and opinion, 2005, Volume: 21, Issue:1 Topics: Aged; Aspirin; Clopidogrel; Cost-Benefit Analysis; Female; Humans; Male; Markov Chains; Middle Aged;	2005
The (variable) definition of benefit in the case of clopidogrel vs aspirin. Archives of internal medicine, 2005, Jun-13, Volume: 165, Issue:11 Topics: Aspirin; Clopidogrel; Humans; Myocardial Infarction; Peripheral Vascular Diseases; Platelet Aggregat	2005
Ultrastructural investigations on protective effects of NCX 4016 (nitroaspirin) on macrovascular endothelium in diabetic Wistar rats. Journal of submicroscopic cytology and pathology, 2005, Volume: 37, Issue:2 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aorta; Aspirin; Diabetes Mellitus, Experimental; E	2005
Impact of metabolic syndrome on prognosis of symptomatic intracranial atherostenosis. Neurology, 2006, May-09, Volume: 66, Issue:9 Topics: Aged; Aspirin; Brain Ischemia; Cohort Studies; Comorbidity; Disease Progression; Double-Blind Method	2006
[Clopidogrel versus acetylsalicylic acid in the secondary prophylaxis of vascular diseases. A commentary on the report of the Institute for Quality and Efficiency in the Health Service]. Der Nervenarzt, 2007, Volume: 78, Issue:2 Topics: Academies and Institutes; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Chemotherapy, Adjuvant;	2007
Consistent platelet inhibition during long-term maintenance-dose clopidogrel therapy among 359 compliant outpatients with documented vascular disease. American heart journal, 2007, Volume: 153, Issue:3 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Clopidogrel; Drug Therapy, Combination; Fema	2007
Can chronic fatigue symptoms associated with nutcracker phenomenon be treated with aspirin? Medical hypotheses, 2007, Volume: 69, Issue:3 Topics: Adolescent; Angioplasty, Balloon; Aorta; Aspirin; Child; Child, Preschool; Fatigue; Fatigue Syndrome	2007
Aspirin resistance and diabetes mellitus. Diabetologia, 2008, Volume: 51, Issue:3 Topics: Aspirin; Blood Platelets; Diabetes Complications; Diabetic Angiopathies; Drug Resistance; Humans; Pl	2008
Residual platelet thromboxane A2 and prothrombotic effects of erythrocytes are important determinants of aspirin resistance in patients with vascular disease. Journal of thrombosis and haemostasis : JTH, 2008, Volume: 6, Issue:4 Topics: Aged; Aspirin; Blood Platelets; Collagen; Cyclooxygenase 1; Cyclooxygenase Inhibitors; Drug Resistan	2008
Platelet activation and atherothrombosis. The New England journal of medicine, 2008, Apr-10, Volume: 358, Issue:15 Topics: Acute Coronary Syndrome; Aspirin; Atherosclerosis; Clopidogrel; Drug Therapy, Combination; Humans; M	2008
Chronic urticaria. Possible causes, suggested treatment alternatives. Postgraduate medicine, 1983, Volume: 74, Issue:3 Topics: Allergens; Aspirin; Chronic Disease; Drug Administration Schedule; Drug Hypersensitivity; Female; Fo	1983
Antiplatelet drugs. British journal of hospital medicine, 1983, Volume: 30, Issue:1 Topics: Aspirin; Blood Platelets; Cerebrovascular Disorders; Coronary Disease; Dextrans; Dipyridamole; Epopr	1983
Prostaglandins and vascular function. Circulation, 1984, Volume: 70, Issue:5 Pt 2 Topics: Aspirin; Blood Platelets; Blood Vessels; Cardiovascular Diseases; Diet; Epoprostenol; Hemostasis; Hu	1984
Model system to study interaction of platelets with damaged arterial wall. I. Inhibition of platelet adhesion to subendothelium by aspirin and dipyridamole. Experimental and molecular pathology, 1984, Volume: 41, Issue:1 Topics: Animals; Arteries; Aspirin; Dipyridamole; Endothelium; Heparin; Male; Microscopy, Electron; Platelet	1984
Eleven year old Caucasian male with fever and cervical lymphadenopathy. South Dakota journal of medicine, 1983, Volume: 36, Issue:1 Topics: Aspirin; Child; Diagnosis, Differential; Humans; Infections; Lymphatic Diseases; Male; Mucocutaneous	1983
[Prevention of vascular complications in polycythemia vera and primary thrombocythemia treated with low doses of acetylsalicylic acid]. Schweizerische medizinische Wochenschrift, 1983, Nov-05, Volume: 113, Issue:44 Topics: Aged; Aspirin; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Polycythemia Ver	1983
Non-surgical management of peripheral vascular disease. British medical journal (Clinical research ed.), 1981, Jan-24, Volume: 282, Issue:6260 Topics: Aspirin; Dipyridamole; Female; Humans; Male; Vascular Diseases	1981
[Uses and limitations of platelet survival time measurements. A critical assay]. Haematologica, 1980, Volume: 65, Issue:6 Topics: Animals; Aspirin; Blood Platelet Disorders; Blood Platelets; Cell Survival; Chromium Radioisotopes;	1980
Studies on platelet aggregation and antiplatelet therapy in blackfoot disease. Taiwan yi xue hui za zhi. Journal of the Formosan Medical Association, 1981, Volume: 80, Issue:9 Topics: Adult; Aged; Aspirin; Dipyridamole; Female; Foot Diseases; Gangrene; Humans; Male; Middle Aged; Plat	1981
[Present situation of therapy with platelet aggregation inhibitors]. Acta medica Austriaca. Supplement, 1982, Volume: 25 Topics: Adult; Aged; Anticoagulants; Aspirin; Cerebrovascular Disorders; Dipyridamole; Humans; Middle Aged;	1982
Platelet factor 4 levels in patients with coronary artery disease. The Journal of laboratory and clinical medicine, 1981, Volume: 97, Issue:3 Topics: Acute Disease; Adult; Aged; Aspirin; Blood Coagulation Factors; Coronary Artery Bypass; Coronary Dis	1981
Aspirin: a drug with a broad spectrum of action. Maryland state medical journal, 1981, Volume: 30, Issue:4 Topics: Aspirin; Humans; Platelet Aggregation; Vascular Diseases	1981
Practical impact of hemorheology on the treatment of chronic peripheral ischemia. Angiology, 1981, Volume: 32, Issue:10 Topics: Ancrod; Aspirin; Blood Viscosity; Chronic Disease; Erythrocyte Count; Fibrinogen; Humans; Intermitte	1981
Which diabetic patients should be taking aspirin? BMJ (Clinical research ed.), 1995, Sep-09, Volume: 311, Issue:7006 Topics: Aspirin; Diabetes Mellitus; Diabetic Angiopathies; Humans; Platelet Aggregation Inhibitors; Risk Fac	1995
Platelet response to vascular surgery--a preliminary study on the effect of aspirin and heparin. Thrombosis research, 1994, Oct-01, Volume: 76, Issue:1 Topics: Adult; Aged; Aspirin; Female; Fibrinogen; Heparin; Humans; Male; Middle Aged; Platelet Aggregation;	1994
Slow release aspirin in the elderly. Journal of the Royal Society of Medicine, 1994, Volume: 87, Issue:3 Topics: Aged; Aged, 80 and over; Aspirin; Delayed-Action Preparations; Female; Humans; Male; Salicylates; Sa	1994
Platelets of patients with peripheral arterial disease are hypersensitive to heparin. Thrombosis research, 1996, Mar-15, Volume: 81, Issue:6 Topics: Adult; Anticoagulants; Arteries; Aspirin; Blood Platelets; Case-Control Studies; Combined Modality T	1996
Presence and treatment of vascular risk factors in patients with vascular cognitive impairment. Archives of neurology, 1997, Volume: 54, Issue:1 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Aspirin; Cognition Disorders; Dementia; Diabetes Complic	1997
Erythrocyte promotion of platelet reactivity decreases the effectiveness of aspirin as an antithrombotic therapeutic modality: the effect of low-dose aspirin is less than optimal in patients with vascular disease due to prothrombotic effects of erythrocyt Circulation, 1998, Feb-03, Volume: 97, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Aspirin; Blood Platelets; Brain Ischemia; Cerebrovascular Disorders;	1998
Clinical safety and efficacy of clopidogrel--implications of the Clopidogrel versus Aspirin in Patients at Risk of Ischemic Events (CAPRIE) study for future management of atherosclerotic disease. Clinical therapeutics, 1998, Volume: 20 Suppl B Topics: Arteriosclerosis; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Humans; Myocardial Infa	1998
Aspirin prophylaxis for vascular disease. Knowledge needs to be used in clinical situations. BMJ (Clinical research ed.), 1998, Nov-07, Volume: 317, Issue:7168 Topics: Aspirin; Evidence-Based Medicine; Fibrinolytic Agents; Humans; Platelet Aggregation Inhibitors; Prac	1998
Aspirin prophylaxis for vascular disease. Carotid endarterectomy should have been mentioned. BMJ (Clinical research ed.), 1998, Nov-07, Volume: 317, Issue:7168 Topics: Aspirin; Endarterectomy, Carotid; Fibrinolytic Agents; Humans; Vascular Diseases	1998
Arachidonic acid-induced hind limb gangrene: a new experimental rat model of peripheral vascular disease. Biological & pharmaceutical bulletin, 1999, Volume: 22, Issue:3 Topics: Animals; Arachidonic Acid; Aspirin; Disease Models, Animal; Disease Progression; Drug Evaluation, Pr	1999
Clopidogrel: a novel antiplatelet agent. Hospital medicine (London, England : 1998), 1999, Volume: 60, Issue:5 Topics: Adenosine Diphosphate; Aspirin; Clopidogrel; Humans; Ischemia; Myocardial Infarction; Platelet Aggre	1999
Mechanism of protection against vascular smoking-induced changes by hormone replacement therapy. Journal of the American College of Cardiology, 2000, Mar-01, Volume: 35, Issue:3 Topics: Arteries; Aspirin; Estrogen Replacement Therapy; Exercise Therapy; Female; Humans; Myocardial Ischem	2000
[Contribution of platelet aggregation inhibitors in the prevention of complications of atherothrombosis]. Presse medicale (Paris, France : 1983), 2000, Apr-08, Volume: 29, Issue:13 Topics: Aspirin; Clinical Trials as Topic; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Risk Factor	2000
Evidence for the mechanism by which eicosapentaenoic acid inhibits human platelet aggregation and secretion - implications for the prevention of vascular disease. Thrombosis research, 1979, Volume: 16, Issue:1-2 Topics: Adenosine Diphosphate; Animals; Aspirin; Blood Platelets; Calcimycin; Collagen; Eicosanoic Acids; Ep	1979
[The effect of Aspisol on platelet function after vascular surgery (author's transl)]. MMW, Munchener medizinische Wochenschrift, 1977, Jul-15, Volume: 119, Issue:28 Topics: Aged; Aspirin; Blood Coagulation Disorders; Drug Therapy, Combination; Female; Humans; Male; Middle	1977
Platelet suppressing drugs in arterial disease. Thrombosis and haemostasis, 1978, Apr-30, Volume: 39, Issue:2 Topics: Anticoagulants; Aspirin; Blood Platelets; Cerebrovascular Disorders; Clofibrate; Humans; Myocardial	1978
Observations with istopirine in the treatment of vascular complications. Therapia Hungarica (English edition), 1976, Volume: 24, Issue:2 Topics: Aged; Arteriosclerosis; Aspirin; Embolism; Female; Humans; Male; Middle Aged; Vascular Diseases	1976
The emergency cold leg. Geriatrics, 1975, Volume: 30, Issue:3 Topics: Aspirin; Dextrans; Embolism; Emergencies; Femoral Artery; Heparin; Humans; Ischemia; Leg; Methods; P	1975
Simultaneous vasculitis in a mother and newborn infant. The Journal of pediatrics, 1975, Volume: 87, Issue:3 Topics: Adult; Arthritis; Aspirin; Female; Gangrene; Gentamicins; Heparin; Humans; Infant, Newborn; Infant,	1975
Aspirin, the ageless remedy? The New England journal of medicine, 1991, Oct-31, Volume: 325, Issue:18 Topics: Aspirin; Depression, Chemical; Humans; Prostaglandins; Vascular Diseases	1991
Occult aspirin intake revealed by a bleeding colonic angiodysplasia. The American journal of gastroenterology, 1991, Volume: 86, Issue:7 Topics: Anemia; Aspirin; Colon; Gastrointestinal Hemorrhage; Humans; Male; Middle Aged; Munchausen Syndrome;	1991
Central retinal artery obstruction in herpes zoster ophthalmicus and cerebral vasculopathy. Annals of ophthalmology, 1990, Volume: 22, Issue:9 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain; Female; Fluorescein Angiography; Fund	1990
Improvement in pulmonary arterial lesions after heartworm removal using flexible alligator forceps. Nihon juigaku zasshi. The Japanese journal of veterinary science, 1990, Volume: 52, Issue:4 Topics: Animals; Aspirin; Dirofilaria immitis; Dirofilariasis; Dog Diseases; Dogs; Female; Hemodynamics; Mal	1990
Endothelium in the pathogenesis of main vascular diseases. Folia haematologica (Leipzig, Germany : 1928), 1989, Volume: 116, Issue:6 Topics: Animals; Arteriosclerosis; Aspirin; Cholic Acid; Cholic Acids; Endothelium, Vascular; Heparin; Homoc	1989
Anticoagulant therapy and cataract surgery. Documenta ophthalmologica. Advances in ophthalmology, 1989, Volume: 72, Issue:3-4 Topics: Anticoagulants; Aspirin; Cataract Extraction; Hemorrhage; Humans; Postoperative Care; Preoperative C	1989
[Chronic treatment of vascular diseases with indobufen]. Minerva cardioangiologica, 1989, Volume: 37, Issue:5 Topics: Adult; Aged; Aspirin; Cerebrovascular Disorders; Dipyridamole; Humans; Isoindoles; Middle Aged; Phen	1989
Analysis of multiple thromboxane metabolites in plasma and urine. Advances in prostaglandin, thromboxane, and leukotriene research, 1987, Volume: 17B Topics: Aspirin; Humans; Thromboxane B2; Thromboxanes; Vascular Diseases	1987
In vitro and ex vivo effects of indobufen on red blood cell deformability. European journal of clinical pharmacology, 1987, Volume: 32, Issue:2 Topics: Aspirin; Drug Interactions; Erythrocyte Deformability; Humans; In Vitro Techniques; Isoindoles; Phen	1987
Vasculitis and myositis secondary to rubella vaccination. Archives of neurology, 1973, Volume: 28, Issue:3 Topics: Arthus Reaction; Aspirin; Child; Humans; Liver; Lymph Nodes; Male; Microscopy, Electron; Muscles; My	1973
[Clinical study of a new antalgic: Propofan]. Lyon medical, 1972, Jan-23, Volume: 227, Issue:2 Topics: Acetaminophen; Adult; Aged; Analgesics; Aspirin; Caffeine; Dextropropoxyphene; Female; Headache; His	1972
The dilemma of a prison doctor. The Hastings Center report, 1972, Volume: 2, Issue:5 Topics: Anesthesia; Arthritis; Aspirin; Behavior Therapy; Delivery of Health Care; Fluphenazine; Hostility;	1972
Drug-induced bleeding. American journal of clinical pathology, 1974, Volume: 61, Issue:5 Topics: Acetaminophen; Anemia, Aplastic; Anticoagulants; Aspirin; Blood Platelets; Bone Marrow; Capillary Fr	1974
[Action of d,1-N-isopropyl-adrenochrom-monosemicarbazon on thrombocytefunction (author's transl)]. Klinische Wochenschrift, 1974, Feb-15, Volume: 52, Issue:4 Topics: Adrenochrome; Aspirin; Blood Cell Count; Blood Platelet Disorders; Blood Platelets; Platelet Adhesiv	1974
Proceedings: Essential thrombocythaemia and peripheral vascular disease. British journal of haematology, 1974, Volume: 27, Issue:2 Topics: Aspirin; Blood Platelet Disorders; Extremities; Humans; Platelet Adhesiveness; Vascular Diseases	1974
Rheumatoid arthritis associated with eosinophilia. Annals of internal medicine, 1971, Volume: 75, Issue:2 Topics: Aged; Antibodies, Anti-Idiotypic; Arthritis, Rheumatoid; Aspirin; Complement System Proteins; Eosino	1971
[Action of Aspirin on the vascular manifestations of thrombocythemia]. Marseille medical, 1972, Volume: 109, Issue:2 Topics: Aspirin; Blood Platelet Disorders; Epinephrine; Humans; Male; Platelet Adhesiveness; Thrombocythemia	1972
[Determination of uric acid in blood. Experimental determination; critical studies of the technics and results]. Quaderni Sclavo di diagnostica clinica e di laboratorio, 1971, Volume: 7, Issue:2 Topics: Adolescent; Adult; Aspirin; Autoanalysis; Female; Gout; Humans; Indicators and Reagents; Kidney Dise	1971
The acute rectal toxicity of acetylsalicylic acid. Canadian journal of physiology and pharmacology, 1966, Volume: 44, Issue:6 Topics: Adrenal Glands; Animals; Aspirin; Ataxia; Body Weight; Brain; Coma; Diarrhea; Diuresis; Dyspnea; Fee	1966
Comparison of flufenamic acid with aspirin and paracetamol in terms of gastrointestinal blood loss. Annals of physical medicine, 1966, Volume: Suppl Topics: Acetaminophen; Aged; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Aspirin; Chromium Isotopes; Fe	1966
[Contribution to the study of cutaneous vasculitis. I. "Allergic vasculitis"]. Archivio italiano di dermatologia, venereologia, e sessuologia, 1966, Volume: 34, Issue:5 Topics: Aspirin; Child; Drug Hypersensitivity; Female; Humans; Hypersensitivity; Male; Middle Aged; Phenacet	1966

aspirin and Vascular Diseases

Research Excerpts

Research

Studies (208)

Authors

Clinical Trials (14)

Trial Overview

Trial Outcomes

All-cause Mortality

All-cause Mortality in LTOLE Part

The First Occurrence of MI, Ischemic Stroke, ALI, or Cardiovascular (CV) Death

The First Occurrence of Myocardial Infarction (MI), Ischemic Stroke, Acute Limb Ischemia (ALI), or Coronary Heart Disease (CHD) Death

The First Occurrence of the Composite Primary Efficacy Outcome, Myocardial Infarction (MI), Stroke, or Cardiovascular (CV) Death

The First Occurrence of the Composite Primary Efficacy Outcome, Myocardial Infarction (MI), Stroke, or Cardiovascular (CV) Death in LTOLE Part

The First Occurrence of the Primary Safety Outcome Major Bleeding Based on a Modification of the International Society on Thrombosis and Haemostasis (ISTH) Criteria

The First Occurrence of the Primary Safety Outcome Major Bleeding Based on a Modification of the International Society on Thrombosis and Haemostasis (ISTH) Criteria in LTOLE Part

Composite of All-cause Mortality and Nonfatal MI

Composite of Ischemic Stroke, Myocardial Infarction, Death From Ischemic Vascular Causes, or Major Hemorrhage

Composite of Ischemic Stroke, Myocardial Infarction, or Death From Ischemic Vascular Causes

Death From Any Cause

Death From Ischemic Vascular Causes

Hemorrhagic Stroke

Ischemic or Hemorrhagic Stroke

Ischemic Stroke

Major Hemorrhage

Major Hemorrhage Other Than Intracranial Hemorrhage

Minor Hemorrhage

Myocardial Infarction

Other Symptomatic Intracranial Hemorrhage

Symptomatic Intracerebral Hemorrhage

Composite Outcome of Stroke, Myocardial Infarction (MI), or Vascular Death (Antiplatelet Comparison Only)

Composite Outcome of Stroke, Myocardial Infarction, Vascular Death, or New or Worsening Congestive Heart Failure (CHF) (Telmisartan vs. Placebo Only)

Number of Patients With First Recurrent Stroke of Any Type, Fatal or Nonfatal (Antiplatelet Comparison Only)

Number of Patients With First Recurrent Stroke of Any Type, Fatal or Nonfatal (Telmisartan vs. Placebo Only)

Number of Patients With New Onset of Diabetes (Telmisartan vs. Placebo Only)

Adjudicated Major Bleedings

Death From Any Cause (Cardiovascular and Noncardiovascular)

Occurrence of Stroke

First Occurence of Any Component of the Composite of Stroke, Non-Central Nervous System (Non-CNS) Systemic Embolism, Myocardial Infarction or Vascular Death as Per Adjudication

Reviews

Trials

Other Studies